

# Cannabis Use Trends in Massachusetts, Findings from the International Cannabis Policy Study, 2019 and 2020

## A Legislative Report and Considerations

July 2022

### Massachusetts Cannabis Control Commission:

Sarah Kim, Interim Chair  
Nurys Z. Camargo, Commissioner  
Ava C. Concepcion, Commissioner  
Kimberly Roy, Commissioner  
Bruce Stebbins, Commissioner

Shawn Collins, Executive Director

### Prepared by the Massachusetts Cannabis Control Commission:

Alexander Colby, MA, Research Analyst  
Olivia Laramie, MA, Research Project Coordinator  
Hailey Pensky, BA, Office Manager  
Marianne Sarkis, PhD, Director of Data Analytics  
Julie K. Johnson, PhD, Director of Research

## Acknowledgements

### Cannabis Control Commission

Alisa Stack, Chief Operating Officer  
Maryalice Curley, Director of Communications

### University of Waterloo

David Hammond, PhD, Professor and Research Chair  
Samantha Goodman, PhD, Research Scientist

**Suggested bibliographic reference format:**

Colby, A., Laramie, O., Pensky, H., Sarkis, M., Johnson, JK., (2022, July). Cannabis Use Trends in Massachusetts, Findings from the International Cannabis Policy Study, 2019-2020. Worcester, MA: *Massachusetts Cannabis Control Commission*.

## Table of Contents

<b>I.</b>	<b>Introduction</b>	10
	Brief History of Cannabis Laws	10
	International	10
	National: United States	10
	<i>Post-Prohibition Legalization</i>	11
	<i>Federal Bills</i>	12
	Massachusetts	13
	<i>Legal Market Update</i>	13
	Figure I. A.1. Adult-Use Market: Licensed, Operational Marijuana Retailers by County, Massachusetts, June 2022	14
	Table I.A.1. Adult-Use Market, Massachusetts: License Types With at Least a Provisional License as of June 2022	15
	<i>Legislative Research Mandate</i>	16
	Cannabis Use Statistics	17
	National Cannabis Use Statistics	17
	<i>Adults</i>	17
	<i>Youth</i>	17
	Massachusetts Cannabis Use Statistics	17
<b>II.</b>	<b>Methods</b>	18
	International Cannabis Policy Study and Survey	18
	Participants	18
	Figure II.B.1. ICPS Survey: Respondents' locations across the Commonwealth	19
<b>III.</b>	<b>Results</b>	20
	A. Demographics	20
	Table III.A.1. Sample Demographics: Age	20
	Table III.A.2. Sample Demographics: Student Status (Any)	20
	Table III.A.3. Sample Demographics: Sex	20
	Table III.A.4. Sample Demographics: Gender	20
	Table III.A.5. Sample Demographics: Race	21
	Table III.A.6. Sample Demographics: Ethnicity	21
	Table III.A.7. Sample Demographics: Income Adequacy	21
	B. Use Frequency	22
	Table III.B.1. Cannabis Use Frequency: Age	23

Figure III.B.2. Cannabis Use Frequency: Age Cohort .....	23
Table III.B.3. Cannabis Use Frequency: Student Status (Any).....	24
Table III.B.4. Cannabis Use Frequency: Sex .....	24
Table III.B.5. Cannabis Use Frequency: Gender.....	24
Table III.B.6. Cannabis Use Frequency: Race .....	25
Table III.B.7. Cannabis Use Frequency: Ethnicity.....	25
Table III.B.8. Cannabis Use Frequency: Income Adequacy .....	26
Figure III.B.9. Cannabis Use Frequency: Income Adequacy .....	26
C.    Age of Cannabis Initiation.....	27
Table III.C.1. Age of Cannabis Use Initiation: Age.....	27
Table III.C.2. Age of Cannabis Use Initiation: Student Status (Any) .....	27
Table III.C.3. Age of Cannabis Use Initiation: Sex.....	27
Table III.C.4 Age of Cannabis Use Initiation: Gender.....	28
Table III.C.5 Age of Cannabis Use Initiation: Race.....	28
Table III.C.6 Age of Cannabis Use Initiation: Ethnicity .....	28
Table III.C.7 Age of Cannabis Use Initiation: Income Adequacy .....	28
D.    Methods of Consumption .....	29
Table III.D.1 Methods of Consumption: Age.....	29
Figure III.D.2. Methods of Consumption, by Age Cohort .....	30
Table III.D.3. Methods of Consumption: Student Status (Any).....	31
Table III.D.4. Methods of Consumption: Sex .....	31
Table III.D.5. Methods of Consumption: Gender .....	32
Table III.D.6. Methods of Consumption: Race .....	32
Table III.D.7. Methods of Consumption: Ethnicity.....	33
Table III.D.8. Methods of Consumption: Income Adequacy .....	33
E.    Sources of Cannabis .....	34
1. Source of Cannabis Access .....	34
Table III.E.1.1. Source of Cannabis Access: Age .....	34
Table III.E.1.3. Source of Cannabis Access: Student Status (Any) .....	36
Table III.E.1.4. Source of Cannabis Access: Sex.....	36
Table III.E.1.5 Source of Cannabis Access: Gender .....	36
Table III.E.1.6. Source of Cannabis Access: Race .....	37
Table III.E.1.7. Source of Cannabis Access: Ethnicity .....	37
Table III.E.1.8. Source of Cannabis Access: Income Adequacy.....	37

2. Legal vs. Illicit Market Sourcing.....	38
a) Legal Market Sourcing .....	38
Table III.E.2. a.1. Percent of Cannabis Purchased Legally .....	38
Figure III.E.2. a.2. Percent of Cannabis Purchased Legally, by Age Cohort.....	39
a) Reasons for Avoiding Legal Purchase.....	40
Table III.E.2.b.1. Reasons for Avoiding Legal Cannabis Purchase: Age .....	40
Table III.E.2.b.2. Reasons for Avoiding Legal Cannabis Purchase: Student Status (Any) ..	41
Table III.E.2.b.3. Reasons for Avoiding Legal Cannabis Purchase: Sex .....	41
Table III.E.2.b.4. Reasons for Avoiding Legal Cannabis Purchase: Gender .....	42
Table III.E.2.b.5. Reasons for Avoiding Legal Cannabis Purchase: Race .....	42
Table III.E.2.b.6. Reasons for Avoiding Legal Cannabis Purchase: Ethnicity .....	43
Table III.E.2.b.7. Reasons for Avoiding Legal Cannabis Purchase: Income Adequacy .....	43
F. Cannabis Knowledge and Social Norms .....	44
1. Cannabis Knowledge.....	44
Figure III.F.1 Questions about Side Effects: Percent Correct by Question.....	45
2. Social Norms .....	46
Table III.F.1. Cannabis Knowledge and Social Norms: Age .....	46
Table III.F.2. Cannabis Knowledge and Social Norms: Student Status (Any) .....	46
Table III.F.3. Cannabis Knowledge and Social Norms: Sex.....	47
Table III.F.4. Cannabis Knowledge and Social Norms: Gender .....	47
Table III.F.5. Cannabis Knowledge and Social Norms: Race.....	48
Table III.F.6. Cannabis Knowledge and Social Norms: Ethnicity .....	48
Table III.F.7. Cannabis Knowledge and Social Norms: Income Adequacy.....	48
G. Risky Behaviors.....	49
1. Driving Behaviors.....	49
Table III.G.1.1. Driving and Riding: Age .....	50
Table III.G.1.2. Driving and Riding: Student Status (Any) .....	50
Table III.G.1.3. Driving and Riding: Sex .....	51
Table III.G.1.4. Driving and Riding: Gender .....	51
Table III.G.1.5. Driving and Riding: Race .....	52
Table III.G.1.6. Driving and Riding: Ethnicity .....	52
Table III.G.1.7. Driving and Riding: Socioeconomic Status/Income Adequacy .....	52
2. Cannabis Use at Work .....	53
Table III.G.2.1. Cannabis Use at Work: Age .....	53

Table III.G.2.2. Cannabis Use at Work: Student Status (Any) .....	53
Table III.G.2.3. Cannabis Use at Work: Sex .....	53
Table III.G.2.4. Cannabis Use at Work: Gender .....	53
Table III.G.2.5. Cannabis Use at Work: Race .....	54
Table III.G.2.6. Cannabis Use at Work: Ethnicity .....	54
Table III.G.2.7. Cannabis Use at Work: Socioeconomic Status/Income Adequacy .....	54
3. Poly-Substance Use .....	54
Table III.G.3.1. Poly-Substance Use: Age .....	55
Figure III.G.3.2. Poly-Substance Use, by Age Group .....	55
Table III.G.3.3. Poly-Substance Use: Student Status (Any) .....	56
Table III.G.3.4 Poly-Substance Use: Sex .....	56
Table III.G.3.5 Poly-Substance Use: Gender .....	56
Table III.G.3.6. Poly-Substance Use: Race .....	57
Table III.G.3.7. Poly-Substance Use: Ethnicity .....	57
Table III.G.3.8. Poly-Substance Use: Income Adequacy .....	57
H. Health Care Use and Cannabis .....	58
1. Health Care Use after Cannabis Consumption .....	58
Table III.H.1.1. Health Care Use after Cannabis Consumption: Age .....	58
Table III.H.1.2. Health Care Use after Cannabis Consumption: Student (Any) .....	58
Table III.H.1.3. Health Care Use after Cannabis Consumption: Sex .....	58
Table III.H.1.4. Health Care Use after Cannabis Consumption: Gender .....	59
Table III.H.1.5. Health Care Use after Cannabis Consumption: Race .....	59
Table III.H.1.6. Health Care Use after Cannabis Consumption: Ethnicity .....	59
Table III.H.1.7 Health Care Use after Cannabis Consumption Income Adequacy .....	59
2. Cannabis for Health Treatment.....	60
Table III.H.2.1. Cannabis for Health Treatment: Age.....	60
Table III.H.2.2. Cannabis for Health Treatment: Student Status (Any).....	60
Table III.H.2.3. Cannabis for Health Treatment: Sex .....	61
Table III.H.2.4. Cannabis for Health Treatment: Gender.....	61
Table III.H.2.5. Cannabis for Health Treatment: Race .....	61
Table III.H.2.6. Cannabis for Health Treatment: Ethnicity.....	61
Table III.H.2.7. Cannabis for Health Treatment: Income Adequacy .....	61
Figure III.H.2.8. Cannabis for Mental Health Treatment, by Use Frequency.....	62
I. History of Cannabis Arrests .....	63

Table III.I.1. History of Cannabis Arrests: Age .....	63
Table III.I.2. History of Cannabis Arrests: Student Status (Any) .....	63
Table III.I.3. History of Cannabis Arrests: Sex .....	63
Table III.I.4. History of Cannabis Arrests: Gender .....	63
Table III.I.5. History of Cannabis Arrests: Race .....	63
Table III.I.6. History of Cannabis Arrests: Ethnicity .....	63
Table III.I.7. History of Cannabis Arrests: Income Adequacy .....	64
J. Limitations.....	65
<b>K. Findings.....</b>	<b>66</b>
Use Frequency.....	66
Age of Cannabis Initiation .....	66
Methods of Consumption.....	66
Sources of Cannabis Access.....	66
Cannabis Knowledge and Social Norms .....	67
Risky Behaviors .....	67
Poly-substance Use .....	67
Health Care Use and Cannabis.....	68
History of Cannabis Arrest.....	68
<b>IV. Policy Considerations for the Commonwealth.....</b>	<b>69</b>
Education and Prevention.....	69
Future Research and Data .....	71
<b>V. References .....</b>	<b>74</b>
<b>VI. Appendices.....</b>	<b>76</b>
Appendix I: Acronyms .....	76
Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics .....	77



## Purpose

This report has been prepared in response to Massachusetts General Law Chapter 94G, Section 17(a) to assess multiple items on the Cannabis Control Commission (Commission)’s research agenda. This legislation section states that: “*The commission shall develop a research agenda in order to understand the social and economic trends of marijuana (“cannabis”) in the commonwealth, to inform future decisions that would aid in the closure of the illicit marketplace and to inform the commission on the public health impacts of marijuana.*” [G. L. c. 94G, § 17a]

The research agenda priority items this report addresses include:

1. patterns of use, methods of consumption, sources of purchase and general perceptions of marijuana among minors, among college and university students, and among adults [G. L. c. 94G, § 17a (i) (partially)];
2. incidents of impaired driving, hospitalization, and use of other health care services related to marijuana use, including a report of the state of the science around identifying a quantifiable level of marijuana-induced impairment of motor vehicle operation and a report on the financial impacts on the state healthcare system of hospitalizations related to marijuana [G. L. c. 94G, § 17a (ii) (partially)];
3. a market analysis examining the expansion or contraction of the illicit marketplace and the expansion or contraction of the legal marketplace, including estimates and comparisons of pricing and product availability in both markets [G. L. c. 94G, § 17a (v) (partially)]; and
4. a compilation of data on the number of civil penalties, arrests, prosecutions, incarcerations, and sanctions imposed for violations of chapter 94C for possession, distribution, or trafficking of marijuana or marijuana products, including the age, race, gender, country of origin, state geographic region, and average sanctions of the persons charged [G. L. c. 94G, § 17a (vii) (partially)].

Additionally, Massachusetts General Law Chapter 94G, Section 17(a) asserts that the Commission shall incorporate available data, annually report on the results of its research, and make recommendations for further research or policy changes.

## Main Findings

### International Cannabis Policy Study, Massachusetts 2019-2020

- Approximately 35% of Massachusetts residents in 2019 and 2020 report using cannabis in the past year, with 13% reporting daily or near daily use.
- Among cannabis users, respondents report flower/dried herb (73%), edibles (61%), and vaporized oils (40%) as the most frequent methods of cannabis consumption.
- Cannabis users most frequently reported sourcing their cannabis from a family member or friend (65%), a licensed dispensary (47%), or an unlicensed dealer (28%).
- 65% of respondents support legalized adult-use cannabis.
- Approximately 14% of cannabis users report driving or operating a vehicle within 2 hours of using cannabis in the year prior to the survey.
- Approximately 12% of cannabis users report using cannabis at work in the past 30 days.
- Reports of cannabis co-use with another substance were common. In total, 45% of cannabis users report using cannabis with alcohol, 35% with cigarettes, 9% with an e-cigarette, and 10% with any other illicit substance.
- Approximately 5% of cannabis users report seeking medical treatment for a cannabis-use reason. Many cannabis users also report using cannabis to improve or manage either mental health (46%) or physical health (39%) symptoms.

## I. Introduction

### Brief History of Cannabis Laws

#### International

Worldwide, cannabis has been used for religious, recreational, and therapeutic purposes for thousands of years, although it has been predominantly illegal since the 1961 United Nations (UN) Single Convention on Narcotic Drugs.

#### National: United States

In the United States (US), cannabis cultivation and use were legal under federal and state laws throughout most of modern American history. In 1611, American cultivators produced hemp for its fiber and seed. Irish physician, William Brooke O'Shaughnessy, introduced human therapeutic use of cannabis into Western medicine in 1839. Cannabis' therapeutic potential was recognized by some US physicians in the 1840s. From 1850 to 1941, cannabis was included in the *United States Pharmacopeia*, an official list of public standards for recognized medicinal drugs. The use of medicinal cannabis decreased as the development of other pharmaceuticals increased (e.g., aspirin, morphine, and other opium-derived drugs).<sup>1</sup>

Social reform policies in the 20<sup>th</sup> century aimed to reduce recreational use of many substances, including cannabis. Increased cannabis use between 1910-1920 led 29 states, including Massachusetts, to pass laws prohibiting the possession or sale of cannabis. In the 1940s, state-level changes in cannabis policy led to amendments to two federal policies: The Uniform Narcotic Drug Act of 1932 and the Marihuana Tax Act of 1937. The Marihuana Tax Act of 1937 moved toward federal criminalization through exorbitant fines for cannabis use, possession, and cultivation.<sup>1</sup>

The Federal Controlled Substance Act (CSA) of 1970 replaced the Marihuana Tax Act and made it illegal under federal law for physicians to prescribe cannabis medicinally. Despite the increasing stringency of federal cannabis policies over time, cannabis consumption continued.

In 1971, President Richard Nixon declared a “War on Drugs,” proclaiming: “America’s public enemy number one in the United States is drug abuse. In order to fight and defeat this enemy, it is necessary to wage a new, all-out offensive.” Nixon’s policies were positioned as efforts to combat the supply chain of illegal drugs that contributed to substance use disorders. However, a disproportionate number of these policies focused on criminal justice enforcement and punishment for drug offenses and created systematic changes in the criminal justice system that to this day disproportionality impact people of color. These policies contributed to the “Law and Order” (i.e., politicization of crime) and “Crime and Punishment” (i.e., a culmination of fear of street crime that created a “moral and justified” reason for the heavy punitive response to drug crime) phenomena.

Currently under the CSA, the US Drug Enforcement Association (DEA) classifies cannabis as a Schedule 1 drug, the most restrictive ranking (“scheduling”) on par with heroin, contending that it has: (1) a high potential for abuse, (2) no current accepted medical use in the US, and (3) a lack of accepted safety for use under medical supervision.<sup>2</sup>

The US Food and Drug Administration (FDA) is responsible for the oversight and implementation of the 1906 Pure Food and Drug Act, which prevents the manufacture, sale, or transportation of adulterated, or misbranded, poisonous, or deleterious foods, drugs, medicines, and liquors. The FDA’s role in the regulation of drugs, which includes cannabis and cannabis-derived products [e.g., Marinol (i.e., dronabinol), Cesamet (i.e., nabilone), Syndros (i.e., dronabinol), Epidiolex (i.e., cannabidiol)], includes a review to determine whether proposed drug products are safe and effective for their intended use before products can go to market. The FDA has not approved the cannabis plant for the treatment of any disease, symptom, or condition, except approved medicines that include cannabis extracts and are approved to treat specific medical conditions.<sup>1</sup>

### *Post-Prohibition Legalization*

Cannabis legalization has occurred on a state-by-state basis. There are three types of cannabis-use policies enacted at the state or local level in the US that allow for legal use, despite its federal status: 1) decriminalization but not regulation or legalization, 2) medicinal cannabis legalization, and 3) recreational or adult-use cannabis legalization.

The first wave of cannabis reform was decriminalization, which replaced criminal sanctions for possession and small-scale distribution of cannabis with civil fines.<sup>2</sup> Decriminalization did not legalize cannabis; however, the movement served as a critical step toward legalization. Since 1972, 26 states and the District of Columbia (DC) have enacted policies decriminalizing small amounts (less than 1.5 oz) of cannabis.<sup>3</sup> Additionally, a federal bill that recently passed in the US House of Representatives, the Marijuana Opportunity Reinvestment and Expungement Act (MORE), would decriminalize cannabis at the federal level if enacted into law.

Medicinal cannabis policies followed the decriminalization wave, including varying provisions for patients with specified medical diagnoses and symptoms to access legal cannabis as a treatment modality. Since 1996 and as of March 2022, 37 states, four territories, and DC enacted varying policies permitting medicinal cannabis programs.<sup>3</sup>

Non-medical, adult-use legalization policies followed medical-specific policies and permit varying provisions for legal cannabis access for adults. Since 2012 and as of March 2022, 18 states, two territories, and DC put in place varying policies and regulations permitting the sale of cannabis for non-medical adult-use for those 21 years-old or older (“21≤”).<sup>3</sup>

It is important to note that cannabis legalization policies (i.e., medicinal and non-medicinal adult-use), have been enacted at the state-level, creating a heterogeneous patchwork of policies, provisions, regulation, and enforcement.<sup>4</sup> This study and subsequent report assesses and is limited to data in the Commonwealth of Massachusetts.

## *Federal Bills*

As of March 2022, there has been significant movement on the federal level regarding cannabis reform. On April 4, 2022, the US House of Representatives passed the Medical Marijuana Research Act, which if passed, would expand the number of federal cannabis research cultivators and permit researchers to study cannabis produced within legal state markets. This would be a critical step for cannabis research, as researchers would have increased access to cannabis for study purposes, permitting better and more varied products for research to assess issues that are currently understudied, including therapeutics effects for specified illnesses and symptoms and acute impairment relating to driving. As of this writing, the Medical Marijuana Research Act is currently in the Senate. The US Senate passed its own cannabis research bill on March 24, 2022. Currently, researchers can only use cannabis grown at the University of Mississippi and the Senate's bill maintains this stipulation. The bill passed in the House would allow for researchers to access cannabis from private businesses.

Other noteworthy bills introduced at the federal level in the last two years include the Marijuana Opportunity Reinvestment and Expungement Act (MORE Act) and the States Reform Act.

The MORE Act was introduced to the US House of Representatives in May 2021. On April 1, 2022, the bill passed in the House and is now in the US Senate for consideration. The MORE Act seeks to decriminalize and de-schedule cannabis to provide for reinvestment in certain populations adversely impacted by the War on Drugs (i.e., disproportionate prohibition and enforcement of cannabis law) and to provide for expungement of certain federal cannabis offenses.

The States Reform Act was introduced to the House floor in November 2021. As of January 2022, the bill remains before the House Subcommittee on Health. The bill seeks to amend the Controlled Substances Act on marijuana by striking “marihuana” and “Tetrahydrocannabinols, except for tetrahydrocannabinols in hemp [...]” from the text. With this change, and other suggested amendments, cannabis would be treated as alcohol is treated at the federal regulatory level.

The Cannabis Administration and Opportunity Act (CAOA) is in draft form. Co-sponsored by Senators Cory Booker (D-NJ), Ronald Wyden (D-OR), and Charles Schumer (D-NY), the CAO A aims to remove cannabis from the federal list of controlled substances and empower states to implement their own cannabis laws. The bill would automatically expunge federal non-violent cannabis crimes and end discrimination in federal public benefits for medical cannabis patients and adult-use consumers. It also creates an “Opportunity Trust Fund” funded by federal cannabis tax revenue to reinvest in the communities most impacted by the War on Drugs.

## Massachusetts


Massachusetts enacted and implemented all three types of cannabis reform in different waves. In all cases, Massachusetts acted via ballot initiatives. The major initiatives are cannabis decriminalization in 2008 with ballot Question 2, “*The Sensible Marijuana Policy Initiative*;” medical cannabis use in 2012 with ballot Question 3, “*An Initiative Petition for a Law for the Humanitarian Medical Use of Marijuana*,” and non-medical adult-use cannabis legalization in 2016 with ballot Question 4, “*Massachusetts Legalization, Regulation and Taxation of Marijuana Initiative*.” With the issuance of ballot Question 3, it is important to note that Medical Marijuana Treatment Centers (MTCs) must be vertically integrated, meaning the company has direct ownership over each aspect of cultivation, production, and dispensing to registered patients.

### *Legal Market Update*

The first MTC in Massachusetts opened in June 2015; the first non-medical adult-use Marijuana Retailer opened in November 2018. As of June 17, 2022, there are 226 adult-use retail establishments across the Commonwealth and 95 MTCs that have commenced operations. Massachusetts is also home to more than 500 other Marijuana Establishments, including Independent Testing Laboratories, Cultivators, Product Manufacturers, and delivery services. The Commission is also currently in the process of welcoming its first Craft Marijuana Cooperatives, with three establishments currently in possession of provisional licenses.

In total, 22,126 persons (“Agents”) were employed by cannabis businesses in Massachusetts in March 2022.

**Figure I. A.1. Adult-Use Market: Licensed, Operational Marijuana Retailers by County, Massachusetts, June 2022**



Notes for Figure I.A.1.:

Visualization of operational Marijuana Retailers by municipality and county. Figure is shaded by density (yellow to green); June 2022. Figure created using the “Adult-Use Marijuana Establishment License and Applications – Approved” dataset from the Commission’s Open Data Catalog. Retrieved from <https://masscannabiscontrol.com/open-data/data-catalog/>.

**Table I.A.1. Adult-Use Market, Massachusetts: License Types With at Least a Provisional License as of June 2022**

License Type	N	Percent of Total
Marijuana Retailer	394	40%
Marijuana Cultivator	293	30%
Marijuana Product Manufacturer	220	22%
Marijuana Microbusiness	22	2%
Independent Testing Laboratory	16	2%
Marijuana Transporter with Other Existing ME License	5	<1%
Third Party Marijuana Transporter	4	<1%
Microbusiness Delivery Endorsement	1	<1%
Marijuana Delivery Operator	18	2%
Delivery Courier	14	1%
Craft Marijuana Cooperative	4	<1%

Notes for Table I.A.1.:

Legal cannabis businesses in Massachusetts by total number (*N*) and percent of total. Table created using the Adult-Use “Marijuana Establishment License and Applications – Approved” dataset from the Commission’s Open Data Catalog. Retrieved from <https://masscannabiscontrol.com/open-data/data-catalog/>.



### *Legislative Research Mandate*

Per the results of ballot Question 4, a legislative effort was enacted to modify the voter initiative. One of those modifications created the enabling legislation, St. 2017, c.55, *An Act to Ensure Safe Access to Marijuana*, which outlined a robust research agenda. The one-time statutes include St. 2017, c.55 [[St. 2017, c. 55, § 30\(f\)](#); [St. 2017, c. 55, § 62](#)] and the annual agenda items are outlined in [G. L. c. 94G, § 17\(a\)](#) and [G. L. c. 94G, § 17\(b\)](#).

Massachusetts General Law c. 94G outlines research agenda items and states: “*The [Cannabis Control] commission shall develop a research agenda in order to understand the social and economic trends of marijuana (“cannabis”) in the commonwealth, to inform future decisions that would aid in the closure of the illicit marketplace and to inform the commission on the public health impacts of marijuana*” and “*the Commission shall incorporate available data, annually report on the results of its research, and make recommendations for further research or policy changes.*”

## **Cannabis Use Statistics**

### **National Cannabis Use Statistics**

#### *Adults*

In 2018, the National Survey on Drug Use and Health (NSDUH) reports that 15.9% of all American respondents reported cannabis use in the past year, but there are notable discrepancies in usage by age group. In the same study, an estimated 34.8% of adults, ages 18-25 years-old, reported use in the previous year, compared to 13.3% of adults ages 26 years or older.<sup>3</sup>

#### *Youth*

Cannabis is the most frequently used drug among youth regardless of the status of cannabis legalization where the respondents live. The 2018 NSDUH reports 12.5% of adolescents ages 12-17 years used cannabis in the past year.<sup>3</sup> Other surveys estimate higher rates of past year cannabis use among adolescents. The Monitoring the Future (MTF), for example, survey reports 23.9% of adolescents sampled in the Grades 8, 10, and 12 used cannabis in the past year.<sup>4</sup> Similarly, the 2019 Youth Risk Behavior Surveillance System (YRBSS) reports 21.7% of adolescents in a high school student sample used cannabis in the past year.<sup>5</sup> Discrepancies between surveys may be a result of differences in survey design and sampling, for example the YRBSS is a public school based survey, which inherently excludes students who are absent or dropped out of public school, whereas NSDUH is a household interview, capturing youth 12 years or older.

### **Massachusetts Cannabis Use Statistics**

After alcohol, cannabis is the most widely used intoxicating substance in the US by many estimates<sup>3,4</sup> and there is evidence that these use rates may be comparatively high among Massachusetts residents. The 2016 Behavioral Risk Factor Surveillance System (BRFSS) reported that 12% of Massachusetts-based respondents used non-medical cannabis in the past year. Rates were particularly high among the 18–34-year-old cohort, with 24.5% reporting past-year non-medical cannabis use.<sup>6</sup>

## II. Methods

### International Cannabis Policy Study and Survey

The International Cannabis Policy Study (ICPS) is designed to examine cannabis policy and the public health impacts of cannabis legalization. The study started in 2018 with annual population-based surveys of Canadian and US residents, and now includes Australia and New Zealand. The study is conducted by Dr. David Hammond and colleagues at the University of Waterloo, British Columbia (BC). While the study assesses hundreds of questions, its primary purpose is five research questions about how changes to cannabis policy are reflected in the:

- 1) Prevalence of cannabis use;
- 2) Scope of the cannabis retail environment (both legal and illicit);
- 3) Risk behaviors and high-risk cannabis use;
- 4) Perceived risks and social norms surrounding cannabis; and
- 5) Efficacy of implemented regulatory policies.

Since 2019, the Commission has contracted with the University of Waterloo to administer this survey to Massachusetts residents. Although many state and national surveillance data, such as the NSDUH, BFFSS, YRBSS, and MTF, assess macro-level trends in substance use, the ICPS is the most comprehensive survey for cannabis use metrics. Where many other surveys aim to achieve a basic understanding of substance use trends overall, the ICPS explicitly focuses on cannabis. This design permits a more comprehensive assessment in both depth and scope of cannabis use and related trends. Further, the primary goals of the ICPS align well with the research mandate in M. G. L. c. 94G, § 17a.

Data in this report includes combined results from Wave 1 (2019) and Wave 2 (2020) surveys of Massachusetts participants.

### Participants

The ICPS recruited participants ages 16-65 years through the Nielsen Consumer Insights Global Panel. The ICPS uses post-stratification survey weights created using age-by-sex-by-state, education, and age-by-smoking status groups.

A total of 4,683 Massachusetts respondents completed the survey between the two samples included in this study [2,476 in 2019 and 2,207 in 2020]. Their responses allow the Commission to assess cannabis use trends by age group, student status, sex, gender, race, ethnicity, and perceived income adequacy, an indicator to assess socioeconomic status. Examining patterns by demographics helps to establish a holistic understanding of how Massachusetts residents of diverse backgrounds use and perceive cannabis.

Participants (“respondents”) are categorized into six age groups based on their age at the time of the survey: 1) 16-20 years, 2) 21-25 years, 3) 26-35 years, 4) 36-45 years, 5) 46-55 years, and 6) 56-65 years old. “Student Status” refers to whether the respondent reports either current school enrollment or school enrollment next term, thus, inclusive of high school or university

attendance. For purposes of this report, analyses compare cannabis use trends between students and non-students.


The ICPS includes both Sex and Gender metrics. The “Sex” metric asks respondents to select their sex at birth (limited to male/female), where the “Gender” metric provides “man” and “woman” with an option to select “other” and write in their preferred identity.

The ICPS includes racial and ethnic identity metrics. For race, the ICPS asks respondents whether they belong to one of six different race groups: 1) Asian, 2) American Indian or Alaskan Native, 3) Black, 4) Native Hawaiian or Pacific Islander, 5) White, and 6) Other/2+ Races. For ethnicity, the ICPS asks respondents whether they identify as Hispanic or Latino.

Finally, the ICPS establishes a rough measure of the participants’ income by asking them about their income adequacy; or how difficult it is to make ends meet. We chose to use a subjective rather than objective (e.g., measurable income) measure of income due to a considerable degree of heterogeneity in per capita income across Massachusetts.<sup>7</sup>

[For more information about the ICPS, please see: <http://cannabisproject.ca/> and *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics and how categorized and coded]

**Figure II.B.1. ICPS Survey: Respondents’ locations across the Commonwealth**



**Notes for Figure II.B.1.:**

The density of responses across Massachusetts represented by color, where dark green represents the highest density and yellow the lowest. Created using respondents’ reported city (where available) from the 2019 & 2020 ICPS surveys.

### III. Results

#### A. Demographics

The total sample for 2019 and 2020 included 4,683 Massachusetts residents ages 16-65 years. The mean age of the sample is 44 years old ( $M = 43.99$ ).

**Table III.A.1. Sample Demographics: Age**

Age Group	N	Percent of Total
16-20	328	7%
21-25	254	5%
26-35	898	19%
36-45	911	19%
46-55	971	21%
56-65	1321	28%

**Table III.A.2. Sample Demographics: Student Status (Any)**

Student Status	N	Percent of Total
Student	606	13%
Non-Student	3958	84%
Don't know/refuse to answer	119	2%

**Table III.A.3. Sample Demographics: Sex**

Sex	N	Percent of Total
Female	3366	72%
Male	1317	28%

**Table III.A.4. Sample Demographics: Gender**

Gender	N	Percent of Total
Woman	3312	70%
Man	1305	28%
Unstated / Refuse to Answer	43	1%
Other	23	<1%

Notes for Tables III.A.1., III.A.2., III.A.3., III.A.4.:

Table III.A.1.: Distribution of respondents by age; Mean age: 43.99 years (SD = 14.14).

Table III.A.2.: Distribution of respondents by their reported current student status (high school or university).

Table III.A.3.: Distribution of respondents by their reported birth sex.

Table III.A.3.: Distribution of respondents by their reported birth sex.

See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics.

**Table III.A.5. Sample Demographics: Race**

<b>Race</b>	<b>N</b>	<b>Percent of Total</b>
White	3891	83%
Black or African American	270	6%
Other/2+ races/Unstated	262	6%
Asian	222	5%
Native, Mainland or Islander	38	1%

**Table III.A.6. Sample Demographics: Ethnicity**

<b>Race</b>	<b>N</b>	<b>Percent of Total</b>
Hispanic	396	8%
Non-Hispanic	4225	90%
Don't know / Refuse to answer	62	1%

**Table III.A.7. Sample Demographics: Income Adequacy**

<b>Income Adequacy</b>	<b>N</b>	<b>Percent of Total</b>
Easy	1497	32%
Difficult	1394	30%
Neither Easy or Difficult	1639	35%
Don't know / refuse	153	3%

Notes for Tables III.A.5., III.A.6., III.A.7.:

Table III.A.5.: Distribution of respondents by their reported race.

Table III.A.6.: Distribution of respondents by their reported ethnicity.

Table III.A.7.: Distribution of respondents by their reported subjective income adequacy, a metric assessing subjective socioeconomic status (“income”).

See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics.

## B. Use Frequency

The ICPS survey asked participants to report on how frequently they use cannabis. Of the Massachusetts residents sampled, 31% report never using cannabis, 34% report use more than 12 months ago, 11% report use within the past 12 months, 6% report use within the past month, 5% report use within the past week, and 13% report use on a daily or almost daily basis. In total, 69% of Massachusetts residents report previous cannabis use over their lifetime and 35% within the past year.

The Commission found notable trends in use frequency by age group. Emerging adults, categorized as respondents ages 16-20 years, were the most likely to have never used cannabis, with over half of this demographic reporting themselves as a “never user.” This information is not entirely surprising, as the legal sale of cannabis in Massachusetts is limited to individuals 21 years of age and older. Individuals ages 21-25 years were the most frequent daily users, with 19% of respondents reporting the daily or almost daily use of cannabis. Cannabis use was also highly frequent in respondents ages 26-35 years, with 18% reporting daily use.

Males and females show similar use frequency patterns. Notably, 31% of the members of each sex report never using cannabis. Whereas 13% of each sex report daily cannabis use. Similar trends emerge when results are observed by gender. Approximately 22% of respondents with a gender identity other than man or woman report daily use; however, this sample accounted for a very small proportion of the population (<1%) that participated in Massachusetts.


There are notable differences between race groups in cannabis use frequency. For example, Asian respondents report cannabis use at much lower rates than the rest of the population, with 72% reporting never using cannabis and just 2% reporting daily use. When added together, 12% of Asian individuals reported cannabis use *of any kind* in the past year. This reporting contrasts with the reported past-year cannabis use frequencies of respondents identifying as White (35% use/year), Black (45% use/year), Native (36% use/year), or Other/2+ races (39% use/year).

Trends in cannabis use frequency show notable patterns when segmented by the perceived income adequacy, the measure assessing subjective socioeconomic status. Among those reporting “Difficult” income adequacy (30%), 17% are daily users, compared to 14% among those reporting “Neither (easy or difficult)” and 9% reporting “Easy” income adequacy. In a similar fashion, just 23% of the “Difficult” group never used cannabis, compared to 33% and 34% in the “Neither” and “Easy” groups, respectively.

**Table III.B.1. Cannabis Use Frequency: Age**

Cannabis use variable	16-20 years	21 – 25 years	26-35 years	36-45 years	46-55 years	56-65 years
N	269	313	898	911	971	1321
Never user	52% (139: 269)	36% (114: 313)	28% (253: 898)	32% (292: 911)	31% (306: 971)	27% (351: 1321)
Used more than 12 months ago	8% (22: 269)	12% (39: 313)	27% (243: 898)	27% (245: 911)	40% (391: 971)	49% (649: 1321)
Past 12-month user	12% (33: 269)	16% (51: 313)	12% (12: 898)	10% (96: 911)	9% (90: 971)	9% (123: 1321)
Monthly user	10% (27: 269)	10% (32: 313)	7% (63: 898)	6% (57: 911)	4% (37: 971)	4% (49: 1321)
Weekly user	5% (14: 269)	5% (16: 313)	7% (65: 898)	6% (59: 911)	5% (47: 971)	4% (54: 1321)
Daily/almost daily user	13% (34: 269)	19% (61: 313)	18% (162: 898)	18% (162: 911)	10% (100: 971)	7% (95:1321)

**Figure III.B.2. Cannabis Use Frequency: Age Cohort**



Notes for Table III.B.1 and Figure III.B.2.:

Cannabis use frequency by age cohort. Respondents were asked “How often do you use marijuana?” and given the options between “Never user,” “Used more than 12 months ago,” “Past 12-month user,” “Monthly user,” “Weekly user,” or “Daily/almost daily user,” Respondents could choose only one response option. For table III.B.1., no statistical comparisons were made due to the categorical nature of this variable.

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]



**Table III.B.3. Cannabis Use Frequency: Student Status (Any)**

Cannabis use variable	Student	Non-Student	Unstated
<i>N</i>	606	3958	119
Never user	40% (244: 606)	30% (1179: 3958)	27% (32: 119)
Used more than 12 months ago	17% (102: 606)	37% (1456: 3958)	26% (31: 119)
Past 12-month user	12% (76: 606)	10% (413: 3958)	13% (16: 119)
Monthly user	9% (56: 606)	5% (203: 3958)	5% (6: 119)
Weekly user	8% (48: 606)	8% (198: 3958)	8% (9: 119)
Daily/almost daily user	13% (80: 606)	13% (509: 3958)	21% (25: 119)

**Table III.B.4. Cannabis Use Frequency: Sex**

Cannabis use variable	Male	Female
<i>N</i>	1317	3366
Never user	31% (413: 1317)	31% (1042: 3366)
Used more than 12 months ago	35% (467: 1317)	33% (1122: 3366)
Past 12-month user	9% (114: 1317)	12% (391: 3366)
Monthly user	5% (68: 1317)	6% (197: 3366)
Weekly user	6% (82: 1317)	5% (173: 3366)
Daily/almost daily user	13% (173: 1317)	13% (441: 3366)

**Table III.B.5. Cannabis Use Frequency: Gender**

Cannabis use variable	Man	Woman	Other	Unstated
<i>N</i>	1305	3312	23	43
Never user	31% (403: 1305)	31% (1021: 3312)	35% (8/23)	54% (23/43)
Used more than 12 months ago	36% (466: 1305)	34% (1114: 3312)	17% (4/23)	12% (5/43)
Past 12-month user	8% (111: 1305)	12% (389: 3312)	13% (3/23)	5% (2/43)
Monthly user	5% (69: 1305)	6% (195/3312)	4% (1/23)	0% (0/43)
Weekly user	6% (82: 1305)	5% (168/3312)	9% (2/23)	7% (3/43)
Daily/almost daily user	13% (174: 1305)	13% (425/3312)	22% (5/23)	23% (10/43)

Notes for Table III.B.3, III.B.4., and III.B.5.:

Cannabis use frequency: Respondents were asked “How often do you use marijuana?” and given the options between “Never user,” “Used more than 12 months ago,” “Past 12-month user,” “Monthly user,” “Weekly user,” or “Daily/almost daily user,” Respondents could choose only one response option. For table III.B.1., no statistical comparisons were made due to the categorical nature of this variable.

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]

**Table III.B.6. Cannabis Use Frequency: Race**

Cannabis use variable	Asian	Black	Native, Mainland or Islander	Other/ 2+ Races	White
<i>N</i>	<b>222</b>	<b>270</b>	<b>38</b>	<b>262</b>	<b>3891</b>
Never user	72% (161: 222)	34% (92: 270)	34% (13: 38)	33% (86: 262)	28% (1103: 3891)
Used more than 12 months ago	14% (32: 222)	20% (55: 270)	29% (11: 38)	27% (72: 262)	36% (1419: 3891)
Past 12-month user	4% (10: 222)	8% (22: 270)	5% (2: 38)	9% (24: 262)	11% (447: 3891)
Monthly user	4% (9: 222)	8% (22: 270)	8% (3: 38)	7% (19: 262)	5% (212: 3891)
Weekly user	2% (5: 222)	7% (19: 270)	10% (4: 38)	4% (11: 262)	6% (216: 3891)
Daily/almost daily user	2% (5: 222)	22% (60: 270)	13% (5: 38)	19% (50: 262)	13% (494: 3891)

**Table III.B.7. Cannabis Use Frequency: Ethnicity**

Cannabis use variable	Hispanic	Non-Hispanic	Unstated
<i>N</i>	<b>396</b>	<b>4255</b>	<b>62</b>
Never user	30% (120: 396)	31% (1308: 4255)	44% (27: 62)
Used more than 12 months ago	25% (98: 396)	35% (1478: 4255)	21% (13: 62)
Past 12-month user	8% (32: 396)	11% (464: 4255)	14% (9: 62)
Monthly user	8% (30: 396)	5% (233: 4255)	3% (2: 62)
Weekly user	7% (29: 396)	5% (219: 4255)	11% (7: 62)
Daily/almost daily user	22% (87: 396)	12% (523: 4255)	6% (4: 62)

Notes for Table III.B.6. and III.B.7.:


Cannabis use frequency: Respondents were asked “How often do you use marijuana?” and given the options between “Never user,” “Used more than 12 months ago,” “Past 12-month user,” “Monthly user,” “Weekly user,” or “Daily/almost daily user,” Respondents could choose only one response option. For table III.B.1., no statistical comparisons were made due to the categorical nature of this variable.

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]

**Table III.B.8. Cannabis Use Frequency: Income Adequacy**

Cannabis use variable	Difficult	Neither	Easy	Unstated
<i>N</i>	1394	1639	1497	153
Never user	23% (325: 1394)	33% (543: 1639)	34% (505: 1497)	54% (82: 153)
Used more than 12 months ago	35% (482: 1394)	32% (524: 1639)	37% (557: 1497)	17% (26: 153)
Past 12-month user	13% (179: 1394)	10% (160: 1639)	10% (149: 1497)	11% (17: 153)
Monthly user	6% (82: 1394)	6% (93: 1639)	5% (80: 1497)	6% (10: 153)
Weekly user	6% (83: 1394)	6% (93: 1639)	5% (75: 1497)	3% (4: 153)
Daily/almost daily user	17% (243: 1394)	14% (226: 1639)	9% (131: 1497)	9% (14: 153)

**Figure III.B.9. Cannabis Use Frequency: Income Adequacy**



Notes for Table III.B.8. and Figure III.B.9.:

Cannabis use frequency: Respondents were asked “How often do you use marijuana?” and given the options between “Never user”, “Used more than 12 months ago”, “Past 12-month user”, “Monthly user”, “Weekly user”, or “Daily/almost daily user”. Respondents could choose only one response option. No statistical comparisons were made due to the categorical nature of this variable. Respondents could choose only one response option. For Table III.B.7., no statistical comparisons were made due to the categorical nature of this variable. Income adequacy refers to metric assessing subjective socioeconomic status.

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]

### C. Age of Cannabis Initiation

For respondents who report cannabis use, the ICPS asks the age when respondents first consumed cannabis (“age of cannabis initiation”). The mean age of first-time cannabis use among the 3,228 individuals in the sample was 19 years-old (SD=7.91). Adults ages 21-25 report a mean age of initiation of 17 years old and respondents ages 16-20 report a mean of under 16 years. Students enrolled at either a high school or university are more likely to initiate their cannabis use at an earlier age, when compared to their non-student counterparts. There are no significant differences in the age of initiation by sex, gender, race, ethnicity, or income adequacy demographics.

**Table III.C.1. Age of Cannabis Use Initiation: Age**

Cannabis use variable	16-20 years	21 – 25 years	26-35 years	36-45 years	46-55 years	56-65 years
<i>N</i>	130	199	645	619	665	970
Age	15.9	17.4	18.5	20.1	19.5	19

**Table III.C.2. Age of Cannabis Use Initiation: Student Status (Any)**

Cannabis use variable	Student	Non-Student	Don’t know/ refuse
<i>N</i>	362	2779	87
Age	18.1	19.2	17.6

**Table III.C.3. Age of Cannabis Use Initiation: Sex**

Cannabis use variable	Female	Male
<i>N</i>	2324	904
Age	18.9	19.3

Notes for Table III.C.1, III.C.2, and III.C.3.:

Respondents reported on the age when they first used cannabis. Respondents were asked “How old were you when you first used marijuana? (Enter age in years)”;

Table III.C.1.:  $p < .001$

Table III.C.2.:  $p = .012$

Table III.C.3.:  $p = .176$

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]

**Table III.C.4 Age of Cannabis Use Initiation: Gender**

Cannabis use variable	Man	Woman	Other	Unstated
<i>N</i>	902	2291	15	20
Age	19.3	18.9	17	18.5

**Table III.C.5 Age of Cannabis Use Initiation: Race**

Cannabis use variable	Asian	Black	Native, Mainland or Island	White	Other
<i>N</i>	61	178	25	2788	176
Age	20.8	19.5	18.4	19	18.5

**Table III.C.6 Age of Cannabis Use Initiation: Ethnicity**

Cannabis use variable	Hispanic	Non-Hispanic	Don't Know/Refuse
<i>N</i>	276	2917	35
Age	19.1	19	20.9

**Table III.C.7 Age of Cannabis Use Initiation: Income Adequacy**

Cannabis use variable	Difficult	Neither	Easy	Unstated
<i>N</i>	777	679	611	49
Age	18.6	18.4	18.9	19.2

Notes for Table III.C.4, III.C.5, III.C.6, and III.C.7.:

Respondents reported on the age when they first used cannabis. Respondents were asked “How old were you when you first used marijuana? (Enter age in years)”; Income adequacy refers to metric assessing subjective socioeconomic status (“income”).

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]

## D. Methods of Consumption

The ICPS survey asks participants that report previous cannabis use which methods of consumption they preferred. Across the entire two-year sample, the three most frequently reported methods of consumption are flower/dried herb (73%), edibles (61%), and vaporized oils (40%). Products such as concentrates, hash/kief, and vaporized oils are more popular with respondents 25 or younger (ages 16-20 and 21-25) than their older counterparts (ages 56-65). THC-infused drinks, hash/kief, and vaporized oils are more popular with the student than non-student population.

**Table III.D.1 Methods of Consumption: Age**


Cannabis use variable	16-20 years	21 – 25 years	26-35 years	36-45 years	46-55 years	56-65 years	<i>p</i>
<i>N</i>	<b>128</b>	<b>137</b>	<b>398</b>	<b>372</b>	<b>274</b>	<b>321</b>	
Concentrates	22% (28: 127)	20% (27: 135)	19% (76: 395)	18% (67: 369)	10% (27: 274)	6% (18: 320)	<.001
Drinks	16% (20: 127)	12% (16: 136)	15% (58: 396)	16% (60: 372)	8% (21: 273)	3% (11: 321)	<.001
Edibles	61% (78: 128)	61% (82: 135)	65% (258: 397)	69% (255: 371)	54% (148: 274)	55% (178: 321)	<.001
Flower	73% (90: 124)	77% (105: 137)	73% (289: 397)	75% (278: 369)	75% (203: 271)	70% (226: 321)	.648
Hash / Kief	28% (35: 124)	22% (30: 135)	24% (96: 397)	21% (79: 367)	13% (35: 274)	10% (33: 319)	<.001
Oils, Oral	21% (27: 126)	24% (33: 135)	27% (106: 397)	30% (113: 371)	22% (61: 272)	24% (77: 321)	.160
Oils, Vaporized	53% (67: 127)	47% (64: 135)	47% (188: 398)	45% (167: 372)	32% (88: 272)	23% (73: 321)	<.001
Tinctures	6% (8: 125)	16% (22: 135)	15% (58: 395)	17% (63: 367)	13% (37: 274)	14% (44: 321)	.091
Topicals	20% (25: 125)	18% (24: 132)	24% (94: 396)	27% (97: 369)	17% (48: 274)	24% (76: 320)	.093

Notes for Table III.D.1.:

Modes of cannabis use. Respondents were asked “Have you used marijuana in any of the following ways?” and given the options: “concentrates”, “drinks”, “edibles”, “flower”, “hash/kief”, “oils, oral”, “oils/vaporized”, “tinctures”, and/or “topicals”. Response items were presented individually.

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]

**Figure III.D.2. Methods of Consumption, by Age Cohort**



Notes for Figure III.D.2.:

Percent of respondents reporting modes of cannabis consumption, by age group. Array of colors represents the different methods of consumption reported on.

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]

**Table III.D.3. Methods of Consumption: Student Status (Any)**

Cannabis use variable	Student	Non-student	Don't know/ Refuse	<i>p</i>
<i>N</i>	<b>254</b>	<b>1316</b>	<b>55</b>	
Concentrates	18% (46: 253)	14% (184: 1312)	24% (13: 55)	.061
Drinks	18% (46: 255)	10% (132: 1315)	15% (9: 55)	.001
Edibles	60% (152: 254)	61% (803: 1317)	75% (41: 55)	.123
Flower	72% (183: 254)	74% (969: 1310)	76% (42: 55)	.691
Hash / Kief	23% (58: 252)	18% (236: 1310)	30% (16: 54)	.021
Oils, Oral	27% (69: 254)	25% (328: 1313)	31% (17: 55)	.540
Oils, Vaporized	48% (122: 254)	37% (487: 1316)	56% (31: 55)	<.001
Tinctures	13% (33: 252)	15% (197: 1311)	9% (5: 54)	.488
Topicals	23% (57: 250)	22% (289: 1312)	26% (14: 54)	.820

**Table III.D.4. Methods of Consumption: Sex**

Cannabis use variable	Male	Female	<i>p</i>
<i>N</i>	<b>431</b>	<b>1194</b>	
Concentrates	18% (79: 430)	14% (164: 1190)	<.001
Drinks	14% (61: 431)	10% (125: 1194)	<.001
Edibles	61% (262: 429)	62% (737: 1197)	<.001
Flower	74% (321: 432)	73% (870: 1187)	.187
Hash / Kief	20% (87: 430)	19% (221: 1186)	<.001
Oils, Oral	25% (106: 428)	26% (311: 1194)	<.001
Oils, Vaporized	36% (154: 431)	41% (493: 1194)	<.001
Tinctures	13% (57: 429)	15% (175: 1188)	<.001
Topicals	15% (65: 429)	25% (299: 1187)	<.001

Notes for Tables III.D.4. and III.D.5.:

Methods of cannabis consumption. Respondents were asked “Have you used marijuana in any of the following ways?” Response items were presented individually.

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]



**Table III.D.5. Methods of Consumption: Gender**

Cannabis use variable	Man	Woman	Other	Unstated	<i>p</i>
<i>N</i>	<b>430</b>	<b>1170</b>	<b>11</b>	<b>15</b>	
Concentrates	19% (81: 429)	13% (151: 1165)	27% (3: 11)	40% (6: 15)	.001
Drinks	14% (60: 430)	10% (117: 1170)	0% (0: 11)	43% (6:14)	<.001
Edibles	61% (261: 428)	61% (715: 1172)	64% (7/: 11)	67% (10: 15)	.977
Flower	75% (323: 431)	73% (849: 1163)	73% (8: 11)	64% (9: 14)	.809
Hash / Kief	21% (90: 429)	18% (209: 1162)	18% (2: 11)	36% (5: 14)	.320
Oils, Oral	25% (107: 427)	26% (304: 1170)	27% (3: 11)	21% (3: 14)	.940
Oils, Vaporized	36% (155: 430)	41% (480: 1170)	45% (5: 11)	57% (8: 14)	.139
Tinctures	13% (56: 428)	15% (175: 1163)	27% (3: 11)	13% (2: 15)	.481
Topicals	16% (69: 429)	25% (290: 1161)	36% (4: 11)	27% (4: 15)	.001

**Table III.D.6. Methods of Consumption: Race**

Cannabis use variable	Asian	Black	Native, Mainland or Island	White	Other	<i>p</i>
<i>N</i>	<b>27</b>	<b>122</b>	<b>13</b>	<b>1361</b>	<b>103</b>	
Concentrates	11% (3/27)	16% (20: 122)	25% (3/12)	15% (203: 1356)	18% (19: 103)	.632
Drinks	10% (3/29)	21% (26: 121)	25% (3/12)	10% (136: 1361)	16% (16: 102)	.001
Edibles	66% (19/29)	59% (71: 121)	64% (7/11)	61% (831: 1362)	70% (72: 103)	.424
Flower	75% (21/28)	74% (90: 121)	77% (10/13)	73% (991: 1357)	79% (79: 100)	.778
Hash / Kief	15% (4/26)	19% (23: 121)	38% (5/13)	19% (257: 1354)	22% (22: 102)	.421
Oils, Oral	25% (7/28)	20% (24: 121)	23% (3/13)	27% (367: 1360)	17% (17: 100)	.124
Oils, Vaporized	55% (16/29)	40% (48: 121)	54% (7/13)	39% (531: 1361)	39% (39: 101)	.399
Tinctures	7% (2/27)	10% (12: 121)	31% (4/13)	15% (203: 1353)	9% (9: 103)	.056
Topicals	22% (6/27)	16% (19: 120)	8% (1/12)	23% (312: 1355)	21% (21: 102)	.261

Notes for Tables III.D.5 and III.D.6.:

Methods of cannabis consumption. Respondents were asked “Have you used marijuana in any of the following ways?” Response items were presented individually.

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]

**Table III.D.7. Methods of Consumption: Ethnicity**

<b>Cannabis use variable</b>	<b>Hispanic</b>	<b>Non-Hispanic</b>	<b>Don't know/Refuse</b>	<b><i>p</i></b>
<i>N</i>	<b>174</b>	<b>1426</b>	<b>20</b>	
Concentrates	23% (40: 174)	14% (200: 1426)	5% (1: 20)	.004
Drinks	18% (31: 172)	11% (158: 1433)	15% (3: 20)	.014
Edibles	59% (103: 174)	62% (889: 1433)	58% (11: 19)	.767
Flower	77% (132: 172)	74% (1057: 1428)	47% (9: 19)	.022
Hash / Kief	25% (43: 173)	18% (256: 1424)	11% (2: 19)	.083
Oils, Oral	28% (49: 173)	26% (372: 1430)	21% (4: 19)	.735
Oils, Vaporized	46% (79: 172)	39% (559: 1434)	53% (10: 19)	.107
Tinctures	17% (30: 174)	14% (199: 1423)	0% (0: 20)	.102
Topicals	24% (41: 173)	22% (313: 1424)	16% (3: 19)	.729

**Table III.D.8. Methods of Consumption: Income Adequacy**

<b>Cannabis use variable</b>	<b>Difficult</b>	<b>Neither</b>	<b>Easy</b>	<b>Unstated</b>	<b><i>p</i></b>
<i>N</i>	<b>583</b>	<b>566</b>	<b>435</b>	<b>43</b>	
Concentrates	17% (99/580)	16% (88/565)	11% (50/433)	14% (6/42)	.104
Drinks	10% (60/583)	11% (65/566)	13% (55/435)	15% (6/41)	.617
Edibles	62% (360/583)	59% (337/566)	64% (279/434)	53% (23/43)	.319
Flower	78% (450/579)	75% (422/564)	68% (294/435)	61% (25/41)	<.001
Hash / Kief	23% (134/580)	19% (109/563)	14% (59/433)	15% (6/40)	.002
Oils, Oral	26% (153/582)	24% (135/564)	28% (122/435)	17% (7/41)	.276
Oils, Vaporized	43% (250/583)	40% (225/565)	36% (155/434)	39% (17/43)	.149
Tinctures	16% (93/578)	13% (72/564)	15% (64/433)	7% (3/42)	.220
Topicals	24% (138/580)	20% (114/562)	24% (104/433)	19% (8/41)	.405

Notes for Tables III.D.7. and III.D.8.:

Methods of cannabis consumption. Respondents were asked “Have you used marijuana in any of the following ways?” Response items were presented individually. For Table III.D.8., Income adequacy refers to metric assessing subjective socioeconomic status (“income”).

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]

## E. Sources of Cannabis

### 1. Source of Cannabis Access

The ICPS asks participants to report where they source their products. The three most popular sources of cannabis in the Massachusetts samples are from a family member/friend (65%), licensed dispensary (47%), and an unlicensed dealer through the illicit market (28%). Notably, 48% of 16-20-year-olds and 41% of 21-25-year-olds reported purchasing their products from an unlicensed dealer. When comparing students to non-students of any age, we observe that 38% of students report buying from an unlicensed dealer, compared to 26% of non-students. Students are also less likely to purchase from a licensed retailer (35%) when compared to non-students (50%).

**Table III.E.1.1. Source of Cannabis Access: Age**


Cannabis use variable	16-20 years	21 – 25 years	26-35 years	36-45 years	46-55 years	56-65 years	<i>p</i>
<i>N</i>	130	138	402	374	274	321	
Dealer	48% (62: 130)	41% (56: 138)	31% (109: 402)	29% (109: 374)	24% (109: 274)	16% (52: 321)	<.001
Delivery service	5% (7: 130)	7% (10: 138)	7% (28: 402)	6% (21: 374)	4% (11: 274)	6% (20: 321)	.671
Family or friend	71% (92: 130)	61% (84: 138)	62% (250: 402)	67% (250: 374)	61% (168: 274)	67% (215: 321)	.226
Self-grown	3% (4: 130)	7% (10: 138)	8% (34: 402)	14% (51: 374)	8% (23: 274)	12% (37: 321)	.005
Licensed store	24% (31: 130)	46% (64: 138)	51% (204: 402)	53% (197: 374)	49% (134: 274)	45% (145: 321)	<.001

Notes for Table III.E.1.:

Respondents were asked: “In the past 12 months, have you gotten any type of marijuana from the following sources? (select all that apply). Licensed Delivery for the nonmedical adult-use market was not operational yet in Massachusetts during time of ICPS data collection, thus, this metric likely captures both illicit market and medical market delivery services.

[See [Appendix II: International Cannabis Policy Study \(ICPS\) Survey Metrics](#) for more information on metrics]

**Figure III.E.1.2. Source of Cannabis Access: Percent Reporting Dealer or Licensed Store by Age**



Notes for Figure III.E.1.2.:

Figure represents the percent of individuals from each group reporting sourcing cannabis from either an unlicensed dealer (yellow) or licensed entity (green).

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]

**Table III.E.1.3. Source of Cannabis Access: Student Status (Any)**

Cannabis use variable	Student	Non-student	Don't know/ Refuse	<i>p</i>
<i>N</i>	<b>260</b>	<b>1323</b>	<b>56</b>	
Dealer	38% (99: 260)	26% (344: 1323)	43% (24: 56)	<.001
Delivery service	7% (19: 260)	6% (75: 1323)	5% (3: 56)	.583
Family or friend	63% (165: 260)	65% (856: 1323)	68% (38: 56)	.814
Self-grown	9% (23: 260)	10% (130: 1323)	11% (6: 56)	.858
Licensed store	35% (90: 260)	50% (655: 1323)	54% (30: 56)	<.001

**Table III.E.1.4. Source of Cannabis Access: Sex**

Cannabis use variable	Male	Female	<i>p</i>
<i>N</i>	<b>437</b>	<b>1202</b>	
Dealer	30% (133: 437)	28% (334: 1202)	.294
Delivery service	6% (27: 437)	6% (70: 1202)	.788
Family or friend	59% (257: 437)	67% (802: 1202)	.003
Self-grown	13% (58: 437)	8% (101: 1202)	.003
Licensed store	49% (213: 437)	47% (562: 1202)	.477

**Table III.E.1.5 Source of Cannabis Access: Gender**

Cannabis use variable	Man	Woman	Other	Unstated	<i>p</i>
<i>N</i>	<b>436</b>	<b>1177</b>	<b>11</b>	<b>15</b>	
Dealer	31% (134:436)	28% (325:1177)	27% (3:11)	33% (5:15)	.637
Delivery service	6% (26:436)	6% (69:1177)	18% (2:11)	0% (0:15)	.270
Family or friend	59% (258:436)	67% (787:1177)	73% (8:11)	40% (6:15)	.006
Self-grown	13% (59:436)	8% (100:1177)	0% (0:11)	0% (0:15)	.007
Licensed store	49% (212:436)	47% (554:1177)	45% (5:11)	27% (4:15)	.406

Notes for Tables III.E.1.3., III.E.1.4., and III.E.1.5.:

Respondents were asked: “In the past 12 months, have you gotten any type of marijuana from the following sources? (select all that apply). Licensed Delivery for the nonmedical adult-use market was not operational yet in Massachusetts during time of ICPS data collection, thus, this metric likely captures both illicit market and medical market delivery services.

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]

**Table III.E.1.6. Source of Cannabis Access: Race**

Cannabis use variable	Asian	Black	Native, Mainland or Island	White	Other	<i>p</i>
<i>N</i>	<b>29</b>	<b>123</b>	<b>14</b>	<b>1369</b>	<b>104</b>	
Dealer	24% (7: 29)	47% (58: 123)	64% (9: 14)	27% (370: 1369)	29% (30: 104)	<.001
Delivery service	14% (4: 29)	9% (11: 123)	14% (2: 14)	5% (68: 1369)	5% (5: 104)	.102
Family or friend	72% (21: 29)	59% (73: 123)	71% (10: 14)	65% (890: 1369)	59% (61: 104)	.287
Self-grown	0% (0: 29)	7% (9: 123)	7% (1: 14)	10% (137: 1369)	12% (13: 104)	.284
Licensed store	41% (12: 29)	40% (49: 123)	50% (7: 14)	48% (657: 1369)	42% (44: 104)	.294

**Table III.E.1.7. Source of Cannabis Access: Ethnicity**

Cannabis use variable	Hispanic	Non-Hispanic	Don't know/Refuse	<i>p</i>
<i>N</i>	<b>178</b>	<b>1439</b>	<b>22</b>	
Dealer	42% (75: 178)	27% (389: 1439)	14% (3: 22)	<.001
Delivery service	6% (14: 178)	6% (86: 1439)	0% (0: 22)	.484
Family or friend	61% (109: 178)	65% (935: 1439)	41% (9: 22)	.060
Self-grown	12% (21: 178)	9% (129: 1439)	14% (3: 22)	.485
Licensed store	42% (75: 178)	48% (691: 1439)	41% (9: 22)	.217

**Table III.E.1.8. Source of Cannabis Access: Income Adequacy**

Cannabis use variable	Difficult	Neither	Easy	Unstated	<i>p</i>
<i>N</i>	<b>587</b>	<b>572</b>	<b>435</b>	<b>45</b>	
Dealer	31% (185: 587)	28% (159: 572)	26% (114: 435)	20% (9: 45)	.140
Delivery service	6% (37: 587)	6% (35: 572)	5% (24: 435)	2% (1: 45)	.700
Family or friend	70% (410: 587)	63% (363: 572)	60% (263: 435)	51% (23: 45)	.003
Self-grown	9% (56: 587)	9% (54: 572)	11% (46: 435)	7% (3: 5)	.822
Licensed store	43% (251: 587)	51% (294: 572)	50% (219: 435)	24% (11/45)	<.001

Notes for Tables III.E.1.6., III.E.1.7., and III.E.1.8.:

Respondents were asked: “In the past 12 months, have you gotten any type of marijuana from the following sources? (Select all that apply). Licensed Delivery for the nonmedical adult-use market was not operational yet in Massachusetts during time of ICPS data collection, thus, this metric likely captures both illicit market and medical market delivery services.

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]

## 2. Legal vs. Illicit Market Sourcing

### a) Legal Market Sourcing

The ICPS asks respondents to estimate what percentage of cannabis they purchased in the past year was derived from legal sources. According to the responses, approximately 64% of all cannabis products were sourced from the legal markets.

**Table III.E.2. a.1. Percent of Cannabis Purchased Legally**


Cannabis use variable	N	Percent Obtained Legally
Flower	896	52%
Edibles	703	66%
Oils, Vaporized	462	61%
Topicals	247	86%
Oils, Oral	203	83%
Tinctures	159	77%
Concentrate	137	58%
<b>Drinks</b>	99	62%

#### Notes for Table III.E.2.a.1:

Percentages represent cannabis obtained legally by *mode of consumption*. Respondents were asked “Overall, about what percentage (%) of the [mode of consumption] that you used in the past 12 months came from [legal, authorized] sources?”

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]

**Figure III.E.2. a.2. Percent of Cannabis Purchased Legally, by Age Cohort**



Notes for Figure III.E.2.a.2:

Percentages represent cannabis overall obtained legally by *age cohort*. Respondents were asked “Overall, about what percentage (%) of the [mode of consumption] that you used in the past 12 months came from [legal, authorized] sources?”

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]



a) Reasons for Avoiding Legal Purchase

The ICPS asks respondents about reasons for purchases from licensed versus unlicensed sources. Respondents reported high prices (34%), less convenience (20%), and the licensed retailer being too far from them (23%) as reasons for using unlicensed sources for cannabis.

**Table III.E.2.b.1. Reasons for Avoiding Legal Cannabis Purchase: Age**

Cannabis use variable	16-20 year	21 – 25 years	26-35 years	36-45 years	46-55 years	56-65 years	<i>p</i>
<i>N</i>	<b>111</b>	<b>107</b>	<b>298</b>	<b>260</b>	<b>186</b>	<b>220</b>	
High Prices	27% (30: 111)	32% (34: 107)	37% (111: 298)	39% (101: 260)	30% (55: 186)	34% (74: 220)	.140
Less Convenient	13% (15: 111)	25% (27: 107)	19% (57: 298)	24% (62: 260)	20% (38: 186)	18% (39: 220)	.160
Too Far	13% (15: 111)	15% (16: 107)	13% (38: 298)	15% (38: 260)	9% (17: 186)	12% (27: 220)	.616
Dealer Loyalty	17% (19: 111)	22% (24: 107)	13% (39: 298)	11% (28: 260)	8% (15: 186)	8% (17: 220)	<.001
Not Anonymous	17% (19: 111)	10% (11: 107)	9% (27: 298)	14% (36: 260)	10% (18: 186)	9% (20: 220)	.122
Requires ID	25% (28: 111)	7% (8: 107)	5% (14: 298)	7% (18: 260)	2% (4: 186)	4% (10: 220)	<.001
Product not offered legally	4% (4: 111)	10% (11: 107)	5% (15: 298)	5% (13: 260)	3% (6: 186)	3% (6: 220)	.056
Cannot buy legally	15% (17: 111)	6% (6: 107)	3% (9: 298)	3% (7: 260)	2% (4: 186)	1% (3: 220)	<.001
Low quality in legal market	4% (5: 111)	6% (7: 107)	3% (9: 298)	5% (12: 260)	2% (4: 186)	4% (9: 220)	.465
Low supply in legal market	4% (5: 111)	7% (8: 107)	4% (13: 298)	7% (18: 260)	2% (3: 186)	2% (5: 220)	.033

Notes for Table III.E.2.b.1:

Percentages represent cannabis overall obtained legally by *age cohort*. Respondents were asked “Overall, about what percentage (%) of the [mode of consumption] that you used in the past 12 months came from [legal, authorized] sources?”

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]

**Table III.E.2.b.2. Reasons for Avoiding Legal Cannabis Purchase: Student Status (Any)**

Cannabis use variable	Non-Student	Student	Unstated	<i>p</i>
<i>N</i>	<b>931</b>	<b>203</b>	<b>48</b>	
High Prices	35% (331: 931)	28% (57: 203)	35% (17: 48)	.125
Less Convenient	21% (198: 931)	15% (30: 203)	21% (10: 48)	.112
Too Far	12% (115: 931)	13% (27: 203)	19% (9: 48)	.420
Dealer Loyalty	12% (111: 931)	12% (24: 203)	15% (7: 48)	.855
Not Anonymous	10% (90: 931)	17% (34: 203)	15% (7: 48)	.010
Requires ID	5% (44: 931)	18% (37: 203)	2% (1: 48)	<.001
Product not offered legally	4% (37: 931)	7% (14: 203)	8% (4: 48)	.094
Cannot buy legally	3% (24: 931)	9% (19: 203)	6% (3: 48)	<.001
Low quality in legal market	4% (34: 931)	4% (9: 203)	6% (3: 48)	.602
Low supply in legal market	4% (37: 931)	5% (11: 203)	8% (4: 48)	.264

**Table III.E.2.b.3. Reasons for Avoiding Legal Cannabis Purchase: Sex**

Cannabis use variable	Male	Female	<i>p</i>
<i>N</i>	<b>309</b>	<b>873</b>	
High Prices	36% (110: 309)	34% (295: 873)	.565
Less Convenient	17% (53: 309)	21% (185: 873)	.128
Too Far	12% (37: 309)	13% (114: 873)	.624
Dealer Loyalty	14% (42: 309)	11% (100: 873)	.321
Not Anonymous	13% (41: 309)	10% (90: 873)	.155
Requires ID	6% (19: 309)	7% (63: 873)	.526
Product not offered legally	7% (19: 309)	4% (34: 873)	.037
Cannot buy legally	4% (38: 873)	3% (8: 309)	.169
Low quality in legal market	5% (16: 309)	3% (30: 873)	.174
Low supply in legal market	5% (15: 309)	4% (37: 873)	.650

Notes for Table III.E.2.b.2 and III.E.2.b.3.:

Respondents were asked “What were the main reasons you bought from illegal/unauthorized sources instead of legal/authorized sources? (please select all that apply).” Percent represents proportion of respondents answering “Yes.”

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]

**Table III.E.2.b.4. Reasons for Avoiding Legal Cannabis Purchase: Gender**

Cannabis use variable	Man	Other	Unstated	Woman	p
<i>N</i>	<b>308</b>	<b>6</b>	<b>14</b>	<b>854</b>	
High Prices	36% (111: 308)	50% (3: 6)	21% (3: 14)	34% (288: 854)	.528
Less Convenient	17% (53: 308)	33% (2: 6)	7% (1: 14)	21% (182: 854)	.213
Too Far	12% (37: 308)	33% (2: 6)	7% (1: 14)	13% (111: 854)	.412
Dealer Loyalty	14% (43: 308)	50% (3: 6)	7% (1: 14)	11% (95: 854)	.016
Not Anonymous	13% (40: 308)	0% (0: 6)	0% (0: 14)	11% (91: 854)	.286
Requires ID	6% (19: 308)	33% (2: 6)	0% (0: 14)	7% (61: 854)	.049
Product not offered legally	7% (22: 308)	0% (0: 6)	0% (0: 14)	4% (33: 854)	.091
Cannot buy legally	3% (8: 308)	17% (1: 6)	7% (1: 14)	4% (36: 854)	.201
Low quality in legal market	5% (16: 308)	0% (0: 6)	0% (0: 14)	3% (30: 854)	.470
Low supply in legal market	5% (15: 308)	0% (0: 6)	0% (0: 14)	4% (37: 854)	.780

**Table III.E.2.b.5. Reasons for Avoiding Legal Cannabis Purchase: Race**

Cannabis use variable	Asian	Black	Native, Mainland or Islander	Other/ 2+ Races	White	p
<i>N</i>	<b>20</b>	<b>101</b>	<b>14</b>	<b>84</b>	<b>963</b>	
High Prices	40% (8: 20)	29% (29: 101)	43% (6: 14)	27% (23: 84)	35% (339: 963)	.371
Less Convenient	30% (6: 20)	24% (24: 101)	21% (3: 14)	18% (15: 84)	20% (190: 963)	.660
Too Far	10% (2: 20)	18% (18: 101)	14% (2: 14)	17% (14: 84)	12% (115: 963)	.378
Dealer Loyalty	15% (3: 20)	23% (23: 101)	14% (2: 14)	11% (9: 84)	11% (105: 963)	.013
Not Anonymous	20% (4: 20)	18% (18: 101)	14% (2: 14)	13% (11: 84)	10% (96: 963)	.092
Requires ID	15% (3: 20)	11% (11: 101)	7% (1: 14)	11% (9: 84)	6% (58: 963)	.109
Product not offered legally	10% (1: 20)	9% (9: 101)	0% (0: 14)	8% (7: 84)	4% (37: 963)	.040
Cannot buy legally	5% (1: 20)	12% (12: 101)	0% (0: 14)	1% (1: 84)	3% (32: 963)	.001
Low quality in legal market	5% (1: 20)	5% (5: 101)	0% (0: 14)	6% (5: 84)	4% (35: 963)	.726
Low supply in legal market	0% (0: 20)	9% (9: 101)	7% (1: 14)	3% (2: 84)	4% (40: 963)	.135

Notes: Respondents were asked “What were the main reasons you bought from illegal/unauthorized sources instead

Notes for Table III.E.2.b.4 and III.E.2.b.5.:

Respondents were asked “What were the main reasons you bought from illegal/unauthorized sources instead of legal/authorized sources? (please select all that apply).” Percent represents proportion of respondents answering “Yes.”

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]

**Table III.E.2.b.6. Reasons for Avoiding Legal Cannabis Purchase: Ethnicity**

Cannabis use variable	Hispanic	Non-Hispanic	Unstated	<i>p</i>
<i>N</i>	<b>148</b>	<b>1015</b>	<b>19</b>	
High Prices	35% (52: 148)	35% (353: 1015)	0% (0: 19)	.006
Less Convenient	20% (29: 148)	21% (209: 1015)	0% (0: 19)	.084
Too Far	12% (18: 148)	13% (132: 1015)	5% (1: 19)	.589
Dealer Loyalty	16% (24: 148)	12% (118: 1015)	0% (0: 19)	.074
Not Anonymous	29% (28: 148)	10% (103: 1015)	0% (0: 19)	.002
Requires ID	9% (13: 148)	7% (67: 1015)	10% (2: 19)	.513
Product not offered legally	9% (13: 148)	4% (41: 1015)	5% (1: 19)	.037
Cannot buy legally	7% (10: 148)	3% (36: 1015)	0% (0: 19)	.114
Low quality in legal market	6% (9: 148)	3% (36: 1015)	5% (1: 19)	.315
Low supply in legal market	5% (7: 148)	4% (44: 1015)	5% (1: 19)	.960

**Table III.E.2.b.7. Reasons for Avoiding Legal Cannabis Purchase: Income Adequacy**

Cannabis use variable	Difficult	Neither	Easy	Don't know	<i>p</i>
<i>N</i>	<b>450</b>	<b>400</b>	<b>296</b>	<b>36</b>	
High Prices	39% (176: 450)	33% (133: 400)	31% (92: 296)	11% (4: 36)	.002
Less Convenient	21% (95: 450)	18% (74: 400)	22% (66: 296)	8% (3: 36)	.180
Too Far	15% (70: 450)	10% (42: 400)	13% (39: 296)	0% (0: 36)	.016
Dealer Loyalty	14% (63: 450)	10% (40: 400)	12% (37: 296)	5% (2: 36)	.195
Not Anonymous	10% (45: 450)	11% (45: 400)	13% (38: 296)	8% (3: 36)	.627
Requires ID	7% (34: 450)	7% (30: 400)	6% (17: 296)	3% (1: 36)	.557
Product not offered legally	5% (21: 450)	4% (15: 400)	6% (18: 296)	3% (1: 36)	.498
Cannot buy legally	3% (14: 450)	4% (17: 400)	5% (14: 296)	3% (1: 36)	.673
Low quality in legal market	4% (20: 450)	3% (13: 296)	3% (13: 296)	0% (0: 36)	.483
Low supply in legal market	5% (22: 450)	4% (15: 400)	4% (13: 296)	5% (2: 36)	.857

Notes for Table III.E.2.b.6 and III.E.2.b.7.:

Respondents were asked “What were the main reasons you bought from illegal/unauthorized sources instead of legal/authorized sources? (please select all that apply).” Percent represents proportion of respondents answering “Yes.”

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]

## F. Cannabis Knowledge and Social Norms


### 1. Cannabis Knowledge

The survey assessed general knowledge and social norms of Massachusetts residents surrounding cannabis, including respondents' favorability of legal cannabis, knowledge of the health effects, and how many of their closest five friends use cannabis. The survey asks participants whether they felt cannabis should be legal and participants could answer: "Legal," "Illegal," "Refuse to Answer," or "Don't Know." It should be noted that Massachusetts has already enacted medical and adult-use cannabis regulations, so this question serves to gauge the public's support for current policies. For the purposes of this question, we report the percentage of respondents who answered that cannabis should be "Legal." Residents overall approve of cannabis, with 65% (2527: 3888) in favor of legal non-medical adult-use cannabis. Subjective approval for legal cannabis notably varied as a function of race. Both white individuals, and those who reported belonging to two or more races, more often approved of legalization, with two thirds of each group (66%) reporting in favor of cannabis legalization. Additionally, just over half of Asian individuals (52%) reported they were in favor of legal cannabis. We observe no significant differences in any other demographic.

The survey also asked participants a series of nine questions about the side effects of cannabis as generally understood by North American researchers. The Commission used these nine questions to form one "cannabis knowledge" variable represented by the percent of cannabis health questions answered correctly. Knowledge of generally accepted side effects was low regardless of demographic group. Participants answered 47% of this set of questions correctly.

However, almost three quarters (73%) of respondents showed knowledge about cannabis' intoxicating effects that make driving or operating machinery dangerous. Conversely, 21% of respondents demonstrated knowledge that regularly using cannabis could increase the risk of psychosis and schizophrenia.

**Figure III.F.1 Questions about Side Effects: Percent Correct by Question**



See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics

## 2. Social Norms

To assess social norms, the ICPS survey asks respondents their five closest friends' cannabis use. On average, respondents report between two to three out of five friends using cannabis.

**Table III.F.1. Cannabis Knowledge and Social Norms: Age**

Cannabis use variable	16-20 years	21 – 25 years	26-35 years	36-45 years	46-55 years	56-65 years	<i>p</i>
<i>N</i>	266	250	896	910	971	1321	
Should cannabis be legal?	61% (126: 207)	70% (175: 250)	67% (506: 751)	64% (486: 764)	64% (521: 809)	64% (713: 1107)	.213
Questions about side effects	47% (266)	41% (312)	43% (896)	46% (910)	50% (971)	51% (1321)	<.001
Friends Using (Of Top 5)	3.03 (185)	2.92 (239)	2.93 (648)	2.83 (577)	2.63 (549)	2.55 (674)	<.001

**Table III.F.2. Cannabis Knowledge and Social Norms: Student Status (Any)**

Cannabis use variable	Student	Non-Student	Don't Know/Refuse	<i>p</i>
<i>N</i>	487	3310	91	
Should cannabis be legal?	65% (319: 487)	65% (2148: 3310)	66% (60: 91)	.949
Questions about side effects	46% (604)	48% (3954)	41% (118)	.582
Friends Using (Of Top 5)	2.92 (430)	2.73 (2365)	3.18 (77)	.001

### Notes for Tables III.F.1 and III.F.2:

Summary of questions (“metrics”) included in tables:

1. **Should cannabis be legal?:** “Should the use of recreational (non-medical) marijuana be (legal/illegal)?” Response represents percent reporting “Legal.”
2. **Questions about side effects:** The percent of questions about cannabis answered correctly. Respondents were asked nine questions about the health effects of cannabis with scientifically supported correct answers.
3. **Friends Using (Of Top 5):** “How many of your five closest friends use marijuana?” Represents the average.

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]

**Table III.F.3. Cannabis Knowledge and Social Norms: Sex**

Cannabis use variable	Male	Female	<i>p</i>
<i>N</i>	<b>1142</b>	<b>2746</b>	
Should cannabis be legal?	67% (767: 1142)	64% (1760: 2746)	.068
Questions about side effects	46% (1315)	48% (3361)	.091
Friends Using (Of Top 5)	2.76 (783)	2.78 (2089)	.735

**Table III.F.4. Cannabis Knowledge and Social Norms: Gender**

Cannabis use variable	Man	Woman	Other	Unstated	<i>p</i>
<i>N</i>	<b>1139</b>	<b>2715</b>	<b>23</b>	<b>11</b>	
Should cannabis be legal?	67% (766: 1139)	64% (1735: 2715)	83% (19: 23)	64% (7: 11)	.068
Questions about side effects	47% (1305)	48% (3310)	56% (23)	21% (38)	<.001
Friends Using (Of Top 5)	2.76 (784)	2.78 (2050)	2.50 (22)	3.06 (16)	.666

Notes for Tables III.F.3 and III.F.4:

Summary of questions (“metrics”) included in tables:

1. **Should cannabis be legal?:** “Should the use of recreational (non-medical) marijuana be (legal/illegal)?” Response represents percent reporting “Legal.”
2. **Questions about side effects:** The percent of questions about cannabis answered correctly. Respondents were asked nine questions about the health effects of cannabis with scientifically supported correct answers.
3. **Friends Using (Of Top 5):** “How many of your five closest friends use marijuana?” Represents the average.

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]



**Table III.F.5. Cannabis Knowledge and Social Norms: Race**

Cannabis use variable	Asian	Black	Native, Mainland or Island	White	Other	<i>p</i>
<i>N</i>	221	270	38	3887	260	
Should cannabis be legal?	52% (84: 160)	63% (135: 213)	57% (17: 30)	66% (2165: 3293)	66% (126: 192)	.011
Questions about side effects	49% (221)	42% (270)	38% (38)	48% (3887)	45% (260)	<.001
Friends Using (Of Top 5)	2.51 (84)	3.28 (176)	2.81 (27)	2.72 (2428)	3.08 (157)	<.001

**Table III.F.6. Cannabis Knowledge and Social Norms: Ethnicity**

Cannabis use variable	Hispanic	Non-Hispanic	Unstated	<i>p</i>
<i>N</i>	395	4222	59	
Should cannabis be legal?	66% (211: 319)	65% (2293: 3535)	68% (23: 34)	.854
Questions about side effects	42% (395)	48% (4222)	39% (59)	<.001
Friends Using (Of Top 5)	3.12 (299)	2.73 (2552)	2.52 (21)	<.001

**Table III.F.7. Cannabis Knowledge and Social Norms: Income Adequacy**

Cannabis use variable	Difficult	Neither	Easy	Unstated	<i>p</i>
<i>N</i>	1394	1639	1495	148	
Should cannabis be legal?	65% (768: 1177)	64% (854: 1342)	66% (862: 1298)	60% (43: 71)	.411
Questions about side effects	46% (1394)	46% (1639)	51% (1495)	33% (148)	<.001
Friends Using (Of Top 5)	2.95 (963)	2.77 (974)	2.57 (879)	2.77 (56)	<.001

Notes for Tables III.F.5, III.F.6., and III.F.7.:

Summary of questions (“metrics”) included in tables:

1. **Should cannabis be legal?:** “Should the use of recreational (non-medical) marijuana be (legal/illegal)?” Response represents percent reporting “Legal.”
2. **Questions about side effects:** The percent of questions about cannabis answered correctly. Respondents were asked nine questions about the health effects of cannabis with scientifically supported correct answers.
3. **Friends Using (Of Top 5):** “How many of your five closest friends use marijuana?” Represents the average.

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]

## **G. Risky Behaviors**

### **1. Driving Behaviors**

The survey assessed respondents' driving behaviors related to cannabis. Questions included whether they have driven a vehicle within two hours of using cannabis ("Cannabis Driver"), whether they have been a passenger to someone driving a vehicle within two hours of using cannabis ("Passenger to Cannabis Driver"), and if they had created a driving plan (e.g., designated driver, taxi, Uber/Lyft, etc.) to avoid driving after using cannabis ("Driving Plan").

Approximately 14% of participants report driving within two hours of using cannabis in the past year. Twenty percent report having been the passenger to a driver that had used cannabis in the prior two hours. Forty-four percent of respondents report creating a driving plan to avoid having to drive after using cannabis.

**Table III.G.1.1. Driving and Riding: Age**

<b>Cannabis use variable</b>	<b>16-20 years</b>	<b>21 – 25 years</b>	<b>26-35 years</b>	<b>36-45 years</b>	<b>46-55 years</b>	<b>56-65 years</b>	<b><i>p</i></b>
<i>N</i>	146						
Cannabis Driver	20% (30: 146)	21% (34: 158)	18% (113: 613)	18% (107: 587)	11% (72: 640)	7% (71: 945)	<.001
Passenger to Cannabis Driver	32% (93: 287)	39% (86: 221)	28% (227: 818)	23% (186: 821)	14% (126: 873)	12% (140: 1206)	<.001
Driving Plan	50% (68: 137)	54% (80: 149)	54% (314: 581)	47% (268: 571)	39% (242: 621)	36% (327: 907)	<.001

**Table III.G.1.2. Driving and Riding: Student Status (Any)**

<b>Cannabis use variable</b>	<b>Student</b>	<b>Non-Student</b>	<b>Unstated</b>	<b><i>p</i></b>
Cannabis Driver	25% (86: 341)	12% (331: 2668)	12% (10: 80)	<.001
Passenger to Cannabis Driver	34% (184: 545)	18% (646: 3580)	28% (28: 101)	<.001
Driving Plan	50% (162: 322)	42% (1085: 2568)	68% (52: 76)	<.001

Notes for Tables III.G.1.1. and III.G.1.2.:

Percent represents the proportion of individuals answering “yes” to each of the following questions:

- 1. Cannabis Driver:** “Have you ever driven a vehicle (e.g., car, snowmobile, motorboat, or an off-road vehicle (ATV)) within 2 hours of using marijuana?”
- 2. Passenger to Cannabis Driver:** “Have you ever been a passenger in a vehicle (e.g., car, snowmobile, motorboat, or an off-road vehicle (ATV) driven by someone who had been using marijuana in the last 2 hours?”
- 3. Driving Plan:** “Have you ever planned ahead or decided NOT to drive to avoid driving high?”

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]

**Table III.G.1.3. Driving and Riding: Sex**

Cannabis use variable	Male	Female	<i>p</i>
Cannabis Driver	18% (156: 861)	12% (271: 2228)	<.001
Passenger to Cannabis Driver	19% (222: 1162)	21% (636: 3064)	<.001
Driving Plan	41% (348: 838)	45% (951: 2128)	<.001

**Table III.G.1.4. Driving and Riding: Gender**

Cannabis use variable	Man	Woman	Unstated	Other	<i>p</i>
Cannabis Driver	18% (157: 861)	12% (266: 2205)	37% (3: 8)	7% (1: 15)	<.001
Passenger to Cannabis Driver	19% (223: 1158)	21% (623: 3029)	40% (6: 15)	25% (6: 24)	.184
Driving Plan	41% (345: 837)	45% (942: 2109)	33% (2: 6)	71% (10: 14)	.057

Notes for Tables III.G.1.3. and III.G.1.4.:

Percent represents the proportion of individuals answering “yes” to each of the following questions:

- b) Cannabis Driver:** “Have you ever driven a vehicle (e.g., car, snowmobile, motorboat, or an off-road vehicle (ATV)) within 2 hours of using marijuana?”
- c) Passenger to Cannabis Driver:** “Have you ever been a passenger in a vehicle (e.g., car, snowmobile, motorboat, or an off-road vehicle (ATV) driven by someone who had been using marijuana in the last 2 hours?”
- d) Driving Plan:** “Have you ever planned ahead or decided NOT to drive to avoid driving high?”

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]

**Table III.G.1.5. Driving and Riding: Race**

Cannabis use variable	Asian	Black	Native, Mainland or Island	Other/ 2+ Races	White	<i>p</i>
Cannabis Driver	10% (6: 58)	25% (41: 165)	14% (3: 22)	18% (30: 164)	13% (347: 2680)	<.001
Passenger to Cannabis Driver	11% (21: 196)	34% (81: 240)	29% (10: 34)	31% (68: 222)	19% (678: 3534)	<.001
Driving Plan	53% (28: 53)	48% (82: 169)	38% (9: 24)	46% (72: 157)	43% (1108: 2563)	.370

**Table III.G.1.6. Driving and Riding: Ethnicity**

Cannabis use variable	Hispanic	Non-Hispanic	Unstated	<i>p</i>
Cannabis Driver	24% (63: 261)	13% (358: 2799)	21% (6: 29)	<.001
Passenger to Cannabis Driver	30% (112: 368)	19% (737: 3816)	21% (9: 42)	<.001
Driving Plan	50% (120: 240)	43% (1168: 2699)	41% (11: 27)	.125

**Table III.G.1.7. Driving and Riding: Socioeconomic Status/Income Adequacy**

Cannabis use variable	Difficult	Neither	Easy	Unstated	<i>p</i>
Cannabis Driver	14% (149: 1028)	15% (152: 1041)	41% (383: 926)	8% (4: 49)	.317
Passenger to Cannabis Driver	26% (341: 1293)	20% (301: 1481)	15% (203: 1355)	13% (13: 97)	<.001
Driving Plan	45% (444: 986)	45% (450: 1009)	41% (383: 926)	49% (22: 45)	.311

Notes for Tables III.G.1.5., III.G.1.6., and III.G.1.7.:

Percent represents the proportion of individuals answering “yes” to each of the following questions:

- e) **Cannabis Driver:** “Have you ever driven a vehicle (e.g., car, snowmobile, motorboat, or an off-road vehicle (ATV)) within 2 hours of using marijuana?”
- f) **Passenger to Cannabis Driver:** “Have you ever been a passenger in a vehicle (e.g., car, snowmobile, motorboat, or an off-road vehicle (ATV) driven by someone who had been using marijuana in the last 2 hours?”
- g) **Driving Plan:** “Have you ever planned ahead or decided NOT to drive to avoid driving high?”

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]

## 2. Cannabis Use at Work

The survey asked respondents, “In the past 30 days, have you used marijuana at work (including breaks) or within 2 hours of starting work?” The tables below show the proportion of respondents who answered “yes.” Twelve percent of respondents report using some form of cannabis while at work. Rates of use at work are higher among younger adults (aged 16-20 years, 21-25 years, and 26-35 years) and those identifying as Hispanic.

**Table III.G.2.1. Cannabis Use at Work: Age**

Cannabis use variable	16-20 years	21 – 25 years	26-35 years	36-45 years	46-55 years	56-65 years	<i>p</i>
Use at work	14% (14: 102)	13% (14: 111)	16% (55: 335)	12% (39: 316)	9% (19: 219)	5% (12: 220)	.002

**Table III.G.2.2. Cannabis Use at Work: Student Status (Any)**

Cannabis use variable	Student	Non-Student	Unstated	<i>p</i>
Use at work	11% (24: 211)	12% (121: 1047)	18% (8: 45)	.440

**Table III.G.2.3. Cannabis Use at Work: Sex**

Cannabis use variable	Male	Female	<i>p</i>
Use at work	13% (46: 351)	11% (107: 952)	.354

**Table III.G.2.4. Cannabis Use at Work: Gender**

Cannabis use variable	Man	Woman	Other	Unstated	<i>p</i>
Use at work	13% (47: 353)	11% (105: 935)	10% (1: 10)	0% (0: 5)	.621

**Table III.G.2.5. Cannabis Use at Work: Race**

<b>Cannabis use variable</b>	<b>Asian</b>	<b>Black</b>	<b>Native, Mainland or Island</b>	<b>Other/ 2+ Races</b>	<b>White</b>	<b><i>p</i></b>
Use at work	11% (3: 27)	15% (15: 100)	27% (3: 11)	18% (12: 68)	11% (120: 1097)	.161

**Table III.G.2.6. Cannabis Use at Work: Ethnicity**

<b>Cannabis use variable</b>	<b>Hispanic</b>	<b>Non-Hispanic</b>	<b>Unstated</b>	<b><i>p</i></b>
Use at work	20% (28: 140)	11% (123: 1105)	15% (2: 13)	.005

**Table III.G.2.7. Cannabis Use at Work: Socioeconomic Status/Income Adequacy**

<b>Cannabis use variable</b>	<b>Difficult</b>	<b>Neither</b>	<b>Easy</b>	<b>Unstated</b>	<b><i>p</i></b>
Use at work	14% (62: 455)	11% (5: /448)	10% (39: 375)	8% (2/25)	.442

### 3. Poly-Substance Use

The ICPS survey asks respondents about whether they used cannabis with other substances. For this survey, “co-use” refers to using cannabis in conjunction with another substance together or within a short time period. The ICPS specifically asks participants to report on which substances they have used “on the same occasion with marijuana in the past 12 months.” The ICPS asks those who reported using cannabis to answer whether they had also used alcohol, cigarettes, electronic cigarettes, or varying illicit substances such as opioids, methamphetamines, and ecstasy while consuming cannabis.

Respondents reported using alcohol with cannabis more than other substances. In fact, 45% of participants reporting using the two substances concurrently in the year previous to the survey. Thirty-five percent of participants report cigarette and cannabis co-use. Older persons (aged 36-45, 46-55, 56-65) reporting higher cigarette co-use rates than their younger counterparts (aged 16-20, 21-25, 26-35). Only 9% of sample report electronic cigarette(s) and cannabis co-use, with rates highest in younger populations. Lastly, 10% of respondents report illicit substance and cannabis co-use. In this population, younger respondents and those with lower perceived income adequacy reporter higher co-use than other groups.


Respondents were asked “which substances they had used on the same occasion with marijuana in the past 12 months” and provided multiple categories of substances, including: alcohol, tobacco, and illicit substances. All substances other than cigarettes, e-cigarettes, and alcohol were collapsed into “illicit substances.”

**Table III.G.3.1. Poly-Substance Use: Age**

Cannabis use variable	16-20 years	21 – 25 years	26-35 years	36-45 years	46-55 years	56-65 years	<i>p</i>
<i>N</i>	121	128	363	355	261	308	
Use with Alcohol	44% (53: 121)	50% (64: 128)	47% (171: 363)	45% (161: 355)	47% (123: 261)	43% (133: 308)	.791
Use with Cigarettes	15% (14: 90)	26% (24: 92)	32% (97: 304)	43% (135: 310)	43% (96: 225)	33% (87: 260)	<.001
Use with E-Cigarettes	25% (26: 103)	23% (21: 90)	13% (35: 262)	13% (35: 261)	7% (13: 173)	6% (10: 179)	<.001
Use with Illicit Substances	11% (9: 81)	12% (9: 72)	11% (27: 237)	13% (26: 201)	9% (14: 147)	2% (3: 152)	.015

**Figure III.G.3.2. Poly-Substance Use, by Age Group**

Percent Reporting Use of Cannabis With...





**Table III.G.3.3. Poly-Substance Use: Student Status (Any)**

Cannabis use variable	Student	Non-student	Don't know	<i>p</i>
<i>N</i>	<b>237</b>	<b>1249</b>	<b>50</b>	
Use with Alcohol	40% (95: 237)	48% (597: 1249)	26% (13: 50)	.001
Use with Cigarettes	25% (47: 186)	36% (383: 1050)	51% (23: 45)	.001
Use with E-Cigarettes	22% (40: 184)	11% (92: 841)	19% (8: 43)	.001
Use with Illicit Substances	11% (16: 149)	9% (62: 705)	28% (10: 36)	.001

**Table III.G.3.4 Poly-Substance Use: Sex**

Cannabis use variable	Male	Female	<i>p</i>
<i>N</i>	<b>398</b>	<b>1138</b>	
Use with Alcohol	50% (198: 398)	45% (507: 1138)	.073
Use with Cigarettes	41% (126: 308)	34% (327: 973)	.019
Use with E-Cigarettes	13% (33: 245)	13% (107: 823)	.849
Use with Illicit Substances	13% (24: 191)	9% (64: 699)	.162

**Table III.G.3.5 Poly-Substance Use: Gender**

Cannabis use variable	Man	Woman	Other	Unstated	<i>p</i>
<i>N</i>	<b>399</b>	<b>1121</b>	<b>11</b>	<b>5</b>	
Use with Alcohol	49% (197: 399)	44% (498: 1121)	73% (8: 11)	40% (2: 5)	.103
Use with Cigarettes	41% (127: 308)	25% (323: 961)	25% (2: 8)	25% (1: 4)	.090
Use with E-Cigarettes	14% (35: 248)	13% (103: 810)	29% (2: 7)	0% (0: 3)	.523
Use with Illicit Substances	13% (25: 195)	9% (63: 686)	0% (0: 7)	0% (0: 2)	.355

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]

**Table III.G.3.6. Poly-Substance Use: Race**

Cannabis use variable	Asian	Black	Native, Mainland or Island	White	Other	<i>p</i>
<i>N</i>	<b>28</b>	<b>110</b>	<b>13</b>	<b>1295</b>	<b>90</b>	
Use with Alcohol	39% (11: 28)	51% (56: 110)	38% (5: 13)	46% (597: 1295)	40% (36: 90)	.530
Use with Cigarettes	15% (4: 26)	33% (29: 89)	25% (2: 8)	36% (390: 1082)	12% (7: 53)	.240
Use with E-Cigarettes	17% (4: 23)	5% (4: 72)	20% (2: 10)	14% (122: 897)	12% (8: 66)	.327
Use with Illicit Substances	0% (0: 19)	12% (8: 68)	14% (1: 7)	10% (72: 743)	13% (7: 53)	.527

**Table III.G.3.7. Poly-Substance Use: Ethnicity**

Cannabis use variable	Hispanic	Non-Hispanic	Unstated	<i>p</i>
<i>N</i>	<b>156</b>	<b>1362</b>	<b>18</b>	
Use with Alcohol	40% (62: 156)	46% (633: 1362)	56% (10: 18)	.198
Use with Cigarettes	33% (43: 130)	36% (407: 1138)	23% (3:13)	.540
Use with E-Cigarettes	18% (21: 117)	13% (118: 939)	8% (1: 12)	.236
Use with Illicit Substances	13% (12: 94)	9% (75: 785)	9% (1: 11)	.613

**Table III.G.3.8. Poly-Substance Use: Income Adequacy**

Cannabis use variable	Difficult	Neither	Easy	Don't know	<i>p</i>
<i>N</i>	<b>562</b>	<b>529</b>	<b>416</b>	<b>29</b>	
Use with Alcohol	45% (255: 562)	45% (237: 529)	49% (202: 416)	38% (11: 29)	.524
Use with Cigarettes	43% (216: 497)	12% (43: 356)	26% (86: 324)	26% (5: 19)	<.001
Use with E-Cigarettes	12% (53: 428)	12% (43: 356)	16% (42: 265)	10% (2: 19)	.497
Use with Illicit Substances	14% (51: 361)	7% (22: 298)	7% (15: 219)	0% (0: 12)	.005

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]

## H. Health Care Use and Cannabis

The ICPS asks respondents about healthcare use in relation to cannabis, both the use of cannabis to treat physical or mental ailments (“proactive care”) and seeking medical treatment due to an adverse outcome from cannabis use (“retroactive care”).

### 1. Health Care Use after Cannabis Consumption

Approximately 5% of respondents report seeking medical services to treat adverse health effects that arise following cannabis consumption (i.e., retroactive care or seeking care due to cannabis use).

**Table III.H.1.1. Health Care Use after Cannabis Consumption: Age**

Cannabis use variable	16-20 years	21 – 25 years	26-35 years	36-45 years	46-55 years	56-65 years	<i>p</i>
<i>N</i>	151	164	617	596	652	959	
Sought health care treatment after cannabis consumption	4% (5: 125)	7% (9: 131)	6% (22: 378)	6% (23: 362)	3% (9: 268)	2% (6: 321)	.039

**Table III.H.1.2. Health Care Use after Cannabis Consumption: Student (Any)**

Cannabis use variable	Student	Non-student	Don’t know	<i>p</i>
<i>N</i>	131	686	54	
Sought health care treatment after cannabis consumption	4% (5: 131)	2% (11: 686)	4% (2: 54)	p<.001

**Table III.H.1.3. Health Care Use after Cannabis Consumption: Sex**

Cannabis use variable	Male	Female	<i>p</i>
<i>N</i>	417	1168	
Sought health care treatment after cannabis consumption	8% (32: 417)	4% (42: 1168)	<.001

Notes for Tables III.H.1.1., III.H.1.2., III.H.1.3.:

Percent represents the proportion of individuals answering “yes” to each of the following question:

1. **Sought Medical Treatment:** “In the past 12 months, did you seek medical help for any adverse or negative health effect(s) caused by using marijuana?”

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]

**Table III.H.1.4. Health Care Use after Cannabis Consumption: Gender**

Cannabis use variable	Man	Woman	Other	Unstated	<i>p</i>
<i>N</i>	417	1149	11	8	
Sought health care treatment after cannabis consumption	8% (32: 417)	4% (42: 1149)	0% (0: 11)	0% (0: 8)	.007

**Table III.H.1.5. Health Care Use after Cannabis Consumption: Race**

Cannabis use variable	Asian	Black	Native, Mainland or Island	White	Other	<i>p</i>
<i>N</i>	28	118	13	1331	95	
Sought health care treatment after cannabis consumption	0% (0: 28)	13% (15: 118)	23% (3: 13)	4% (49: 1331)	7% (7: 95)	<.001

**Table III.H.1.6. Health Care Use after Cannabis Consumption: Ethnicity**

Cannabis use variable	Hispanic	Non-Hispanic	Unstated	<i>p</i>
<i>N</i>	170	1396	19	
Sought health care treatment after cannabis consumption	11% (18: 170)	4% (54: 1396)	10% (2: 19)	<.001

**Table III.H.1.7 Health Care Use after Cannabis Consumption Income Adequacy**

Cannabis use variable	Difficult	Neither	Easy	Don't know	<i>p</i>
<i>N</i>	574	553	425	33	
Sought health care treatment after cannabis consumption	5% (29: 574)	4% (22: 553)	5% (23: 425)	0% (0: 33)	.404

Notes for Tables III.H.1.4, III.H.1.5, III.H.1.6, and III.H.1.7.:

Percent represents the proportion of individuals answering “yes” to each of the following question:

1. **Sought Medical Treatment:** “In the past 12 months, did you seek medical help for any adverse or negative health effect(s) caused by using marijuana?”

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]

## 2. Cannabis for Health Treatment

Forty-six percent of cannabis users report using cannabis to assist with mental health ailments and 39% report using cannabis to assist with physical health ailments (i.e., proactive care or using cannabis to assist with a pre-existing mental or physical health symptom or condition). The respondents in this group may not be part of the Massachusetts Medical Use of Marijuana Program. Given the reporting above relative to how respondents source cannabis, they may be reporting medical use without a healthcare professional's recommendation, or with a recommendation but choosing not to use the medical program.

**Table III.H.2.1. Cannabis for Health Treatment: Age**

Cannabis use variable	16-20 years	21 – 25 years	26-35 years	36-45 years	46-55 years	56-65 years	<i>p</i>
<i>N</i>	151	164	617	596	652	959	
Use to Manage Mental Health	64% (97: 151)	63% (103: 164)	61% (374: 617)	52% (309: 596)	29% (185: 647)	17% (162: 958)	<.001
Use to Manage Physical Health	58% (86: 148)	67% (110: 163)	61% (377: 614)	56% (333: 594)	38% (250: 652)	32% (304: 959)	<.001

**Table III.H.2.2. Cannabis for Health Treatment: Student Status (Any)**

Cannabis use variable	Student	Non-student	Don't know	<i>p</i>
<i>N</i>	346	2708	82	
Use to Manage Mental Health	60% (209: 346)	36% (963: 2705)	71% (58: 82)	p<.001
Use to Manage Physical Health	64% (217: 341)	44% (1187: 2708)	69% (56: 81)	p<.001

Notes for Tables III.H.2.1. and III.H.2.2.:

Percent represents the proportion of individuals answering “yes” to each of the following questions:

1. **Cannabis Use to Manage Mental Health:** “Have you ever used marijuana to improve or manage symptoms for any of the following: (select all that apply)?”
2. **Cannabis Use to Manage Physical Health:** “Have you ever used marijuana to improve or manage symptoms for any of the following: (select all that apply)?”

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]

**Table III.H.2.3. Cannabis for Health Treatment: Sex**

Cannabis use variable	Male	Female	<i>p</i>
<i>N</i>	865	2269	
Use to Manage Mental Health	35% (299: 864)	41% (931: 2269)	<.001
Use to Manage Physical Health	41% (354: 865)	49% (1106: 2265)	<.001

**Table III.H.2.4. Cannabis for Health Treatment: Gender**

Cannabis use variable	Man	Woman	Other	Unstated	<i>p</i>
<i>N</i>	864	2247	15	10	
Use to Manage Mental Health	35% (301: 863)	40% (911: 2247)	73% (11: 15)	80% (8: 10)	<.001
Use to Manage Physical Health	41% (354: 864)	48% (1086: 2241)	80% (12: 15)	80% (8: 10)	<.001

**Table III.H.2.5. Cannabis for Health Treatment: Race**

Cannabis use variable	Asian	Black	Native, Mainland or Island	White	Other	<i>p</i>
<i>N</i>	59	169	25	2717	167	
Use to Manage Mental Health	37% (22: 59)	59% (100: 169)	68% (17: 25)	37% (1010: 2713)	48% (81: 167)	<.001
Use to Manage Physical Health	45% (26: 58)	63% (105: 167)	78% (18: 23)	45% (1220: 2717)	55% (91: 165)	<.001

**Table III.H.2.6. Cannabis for Health Treatment: Ethnicity**

Cannabis use variable	Hispanic	Non-Hispanic	Unstated	<i>p</i>
<i>N</i>	267	2839	31	
Use to Manage Mental Health	61% (161: 265)	37% (1060: 2839)	31% (9: 29)	<.001
Use to Manage Physical Health	64% (172: 267)	45% (1274: 2832)	45% (14: 31)	<.001

**Table III.H.2.7. Cannabis for Health Treatment: Income Adequacy**

Cannabis use variable	Difficult	Neither	Easy	Don't know	<i>p</i>
<i>N</i>	1040	1063	979	52	
Use to Manage Mental Health	48% (500: 1040)	39% (411: 1062)	30% (297: 979)	42% (22: 52)	<.001
Use to Manage Physical Health	54% (566: 1040)	50% (531: 1063)	35% (344: 975)	36% (19: 52)	<.001


Notes for Table III.H.2.3., III.H.2.4., III.H.2.5., III.H.2.6., III.H.2.7.:

Percent represents the proportion of individuals answering “yes” to each of the following questions:

2. **Cannabis Use to Manage Mental Health:** “Have you ever used marijuana to improve or manage symptoms for any of the following: (select all that apply)?”
3. **Cannabis Use to Manage Physical Health:** “Have you ever used marijuana to improve or manage symptoms for any of the following: (select all that apply)?”

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]

**Figure III.H.2.8. Cannabis for Mental Health Treatment, by Use Frequency**



Notes for Figure III.H.2.8.:

Figure represents reported use frequency patterns of individuals by tendency to use cannabis to manage mental health symptoms.

[See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics]

## I. History of Cannabis Arrests

Participants were asked whether they had been arrested for: 1) cannabis possession; and 2) cannabis trafficking, cultivation, or importation. These two variables were aggregated into one variable to indicate whether the individual reported *any* previous arrest (i.e., arrest for possession, distribution, or both). Approximately 4% of respondents report a cannabis arrest. Respondents more likely to report any arrest were younger, male, student, and Black, Hispanic and Native/Mainland or Islander.

**Table III.I.1. History of Cannabis Arrests: Age**

Cannabis use variable	16-20 years	21 – 25 years	26-35 years	36-45 years	46-55 years	56-65 years	<i>p</i>
History of Cannabis Arrest	6% (18: 308)	5% (12: 243)	4% (38: 861)	6% (50: 884)	4% (36: 955)	2% (31: 1315)	<.001

**Table III.I.2. History of Cannabis Arrests: Student Status (Any)**

Cannabis use variable	Student	Non- Student	Unstated	<i>p</i>
History of Cannabis Arrest	7% (42: 565)	4% (141: 3891)	2% (2: 110)	<.001

**Table III.I.3. History of Cannabis Arrests: Sex**

Cannabis use variable	Male	Female	<i>p</i>
History of Cannabis Arrest	7% (91: 1280)	3% (94: 3286)	<.001

**Table III.I.4. History of Cannabis Arrests: Gender**

Cannabis use variable	Man	Woman	Other	Unstated	<i>p</i>
History of Cannabis Arrest	7% (89: 1274)	3% (89: 3249)	4% (1: 25)	33% (6: 18)	<.001

**Table III.I.5. History of Cannabis Arrests: Race**

Cannabis use variable	Asian	Black	Native, Mainland or Island	Other	White	<i>p</i>
History of Cannabis Arrest	3% (7: 213)	10% (26: 256)	8% (3:36)	5% (12: 245)	4% (137: 3816)	<.001

**Table III.I.6. History of Cannabis Arrests: Ethnicity**

Cannabis use variable	Hispanic	Non-Hispanic	Unstated	<i>p</i>
History of Cannabis Arrest	8% (29: 376)	4% (154: 4145)	4% (2: 45)	<.001



**Table III.I.7. History of Cannabis Arrests: Income Adequacy**

<b>Cannabis use variable</b>	<b>Difficult</b>	<b>Neither</b>	<b>Easy</b>	<b>Unstated</b>	<b><i>p</i></b>
History of Cannabis Arrest	4% (62: 1370)	3% (56: 1606)	4% (62: 1468)	4% (5: 122)	.528

See *Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics* for more information on metrics.

## J. Limitations

Given the relative newness of cannabis regulation, there are many research topics and policies to consider in order to understand the landscape. Public health surveillance system surveys most frequently capture lifetime, past-year, or past-month cannabis use. Among people that reply affirmatively to using cannabis in the 2019-2020 ICPS study, there is substantial variation in methods and patterns of use. Understanding this variation is key to defining and making decisions related to cannabis legalization and outcomes from it. For example, given that most respondents in this report showed a preference to use the unregulated market, policymakers and legislators may seek to understand more about this choice, particularly as it relates to tax revenue estimates and safety for medical users. Similarly, the number of respondents seeking medical assistance due to an adverse effect of cannabis use can provide insight into unhealthy cannabis use patterns and alert policymakers where education, prevention mechanisms, or additional healthcare resources may be warranted. With such conclusions, it is important to note, however, that surveys such as the ICPS are limited since they are designed to measure changes at the population level (vs. individual-level change) at a given timepoint.

Another important aspect to consider is the potential influence of municipal level policies that may bias results if multiple jurisdictions in a legalized state do not allow retail stores and/or delivery options. Of the 351 municipalities in Massachusetts, 111 (about 32%) banned retail sale of adult-use cannabis. It is difficult for researchers and regulators to understand and report on how Massachusetts' cannabis policies are associated with illicit market access and/or health impacts, as the association between cannabis use patterns and municipal policy heterogeneity is not understood.

## **K. Findings**

### **Use Frequency**

According to the ICPS survey results, about 35% of respondents reported using any form of cannabis in the past year. Although rates of lifetime use are comparable, younger demographics are more likely to engage in more frequent use with 34% of the respondents ages 21-25 years reporting cannabis use in the month prior, compared to 15% of respondents ages 56-65 years.

### **Age of Cannabis Initiation**

Across our sample, respondents report initiating cannabis use at 19 years old, on average. The age of cannabis initiation is consistent across demographic stratifications. Respondents ages 16-20 years report first using cannabis at a younger age (mean of 15.9 years) than those ages 21-25 (17.4 years).

### **Methods of Consumption**

The most popular means of consumption among Massachusetts residents are flower, edibles, and vaporized oils; however, methods of consumption show different patterns for different age groups. Concentrates and vaporized oils are more popular with adults under 25 years of age.

By study estimates, among these younger demographics (age groups 16-20 years and 21-25 years) compared to older individuals (age group 56-65 years). These numbers are consistent with other studies that find youth are frequent users of concentrates.<sup>8</sup> Research suggests that youth rates of using concentrated THC may warrant monitoring due to the heightened risk for cannabis-use disorder and other consequences during adolescence.<sup>9,10</sup> Similarly, frequency of concentrate use among young adults warrants monitoring because high-potency cannabis products may put users at a higher risk of developing cannabis dependence<sup>11</sup> or experiencing adverse mental health symptoms.<sup>12</sup> Little research has investigated the impact(s) of concentrates on youth groups specifically.

The percentage of middle and high-schoolers in Colorado who reported concentrate use for non-medical purposes increased from 5.7% to 10.2% from 2015 to 2019.<sup>13</sup> It remains to be seen whether the popularity of concentrates is increasing at comparable rates among Massachusetts youth.

### **Sources of Cannabis Access**

The regulated market in Massachusetts continues to grow, although neither the medical nor the adult-use market are fully saturated. This study finds, however, that individuals still source their cannabis from the illicit market with trends in the both the types of cannabis products as well as sourcing of cannabis products across different demographic groups.

Approximately 64% of all cannabis products sourced were from the regulated market, however, there are notable discrepancies by product type. Tinctures (77%), liquid drops (83%), and

topicals (86%) are more frequently sourced from the regulated market than other products, such as concentrates (58%) and flower (52%).

Younger adults report greater rates of purchasing cannabis from illicit market dealers (48% of respondents ages 16-20 years and 41% of respondents ages 21-25 years) compared to older adults (24% of respondents ages 46-55 years and 16% of respondents ages 56-65 years). Conversely, older adults report greater rates of purchasing from licensed retailers/stores (49% of respondents ages 46-55 years and 45% of respondents ages 56-65 years) when compared to younger respondents (24% of respondents ages 16-20 years).

Individuals report different reasons for sourcing products from the illicit market. Rationale for illicit market sourcing includes: 1) expense (34%), and 2) location of licensed options being “too far” (23%). This latter rationale could be affected by the licensing of Delivery Couriers and Delivery Operators in Massachusetts in future years.

### **Cannabis Knowledge and Social Norms**

Data show that residents are in support of legalization regardless of age. Findings showing relatively low understanding of the potential negative side effects of cannabis use are consistent with Goodman and Hammond, who observed a similarly low knowledge of cannabis side effects among Canadian and American participants.<sup>14</sup> This level of knowledge is aligned with the reported risky behaviors summarized below.

### **Risky Behaviors**

In this survey, three categories of risk-taking behaviors were assessed: 1) driving and riding behaviors, 2) cannabis use at work, and 3) poly-use of cannabis with other substance(s). In total, 12% of our sample report driving under the influence of cannabis in the past year. This reporting appears to be a particular issue for youth and younger adults, with one out of five respondents ages 16-20 years and 21-25 years reporting driving within two hours of cannabis use within the past year. Males were more likely to drive within two hours of cannabis use despite comparable rates of cannabis use among males and females. We observed similar rates of cannabis use at work for non-medical purposes, with approximately 12% of respondents reporting some form of cannabis use at work.

### **Poly-substance Use**

According to the survey, respondents frequently co-used cannabis with other substances, such as alcohol, tobacco, and illicit substances. Approximately half of study respondents report using cannabis with alcohol. Cannabis is frequently used with tobacco; however, the method of tobacco administration differs by age group. Over one-third (35%) of respondents report the poly use of cigarettes with cannabis; however, rates are considerably lower in younger demographics (15% of respondents ages 16-20 years and 26% of respondents ages 21-25 years). Poly use of cannabis with e-cigarettes is reported less by comparison, with just 9% of respondents reporting e-cigarette and cannabis co-use. E-cigarettes were used with cannabis at a much higher rate by younger respondents, with 25% of respondents ages 16-20 years and 23% of respondents ages

21-25 years reporting co-use. Additionally, one out of ten respondents report co-use of cannabis and illicit substance(s), a trend warranting additional research and monitoring.

### **Health Care Use and Cannabis**

In this study, respondents report varied experiences with healthcare related to cannabis. First, the use of cannabis did not frequently result in the use of healthcare services due to an adverse outcome from cannabis use, with one out of 20 respondents reporting seeking healthcare services for a negative cannabis-related incident. Conversely, approximately half (46%) of respondents report using cannabis to regulate mental health concerns (e.g., anxiety, depression, bipolar disorder) and 39% report using cannabis to alleviate physical pain. Notably, younger individuals (ages 16-20 years and 21-25 years) and those of lower perceived income (e.g., those reporting making ends meet as “Very difficult” or “Difficult”) were also more likely to report using cannabis to manage their mental and/or physical health.

### **History of Cannabis Arrest**

Approximately 4% of respondents report a previous cannabis arrest. Although this rate itself may not warrant concern, there were notable discrepancies in reported arrests by demographic groups. Males, students, and Black, Hispanic, and Native/ Mainland or Islander individuals report higher rates of previous arrests than their counterparts. It is important to note that out of all race and ethnic categories, Black respondents report the highest rate of cannabis arrest (10%).

## IV. Policy Considerations for the Commonwealth

Based on this assessment of cannabis use trends in Massachusetts from 2019-2020, the Commission offers the following considerations for policymakers in the Commonwealth. These considerations echo previous reports, including those from past ICPS findings. In fact, this report and survey on which it is based underscore the value of several Commission programs that are underway or planned for the future.

### Education and Prevention

Education about cannabis policy, regulations, and safe use continues to be important to mitigate potential adverse effects, including planning for driving or using machinery after cannabis use and understanding the negative side effects. Data shows gaps in knowledge of Massachusetts-specific policies and regulations and the value of the regulated market. It is critical that the Commonwealth has a layered approach to education and prevention to reach varying groups, including efforts at the individual, interpersonal, community, and society levels.

**Consideration 1:** The Commission could continue to support and seek funding for continuing the Public Awareness Campaign started with the Department of Public Health in 2018.

Additional pre-and-post survey assessments of the public awareness campaign continuation could be used to monitor constituents' knowledge of cannabis policies, risks, social norms, and change in knowledge over time. If funded, the Commission should consider a focus on macro-level policy education, youth and emerging adult prevention, and education on adverse consequences and harm mitigation, such as focus on the following areas warranting education based on study findings:

- Cannabis risks including differential effects of varying methods of consumption, substance use dependence potential, pregnant and breastfeeding women risks, youth risks, driving and riding with impaired driving risks, inhalation risks, high potency risks, mental health risks, and poly-substance use risks. [See Sections: 1) *III.D. Methods of Consumption*, 2) *III.F. Cannabis Knowledge and Social Norms*, and 3) *III.G.1. Driving and Riding Behaviors*]
- Where and under what circumstances cannabis is safe to consume, such as at the workplace. [See Section, *III.G.2. Use at Work*]

[See Reports: (1) *A Baseline Review and Assessment of Cannabis Use and Youth: Literature Review and Preliminary Data in Massachusetts*, Sections: (A) *IX. Public Health Framework: Commonwealth of Massachusetts: Regulations and Public Health* and (B) *Appendix VI: Public Awareness Campaigns*; and (2), *More About Marijuana Public Awareness Campaign Effectiveness*, and 3) *A Baseline Review and Assessment of Cannabis Use and Public Safety Part 1: Operating under the Influence of Cannabis: Literature Review and Preliminary Data in Massachusetts*]

**Consideration 2:** The Commission could continue and build on the systematic approach to the Responsible Vendor Training (RVT) Program to ensure annual evidence-based education for all cannabis industry agents in accordance with Commission adult-use and medical marijuana regulations. New research and data should be incorporated into the RVT curriculum as new information is learned, such as foci on impaired driving, cognitive effects, and changes in policy and/or regulation. The program should be evaluated to assess effectiveness and areas of improvement. [See Sections: 1) *III.D. Methods of Consumption*, 2) *III.F. Cannabis Knowledge and Social Norms*, 3) *III.G.1. Driving and Riding Behaviors*, and 4) *III.I.1. Health Care Use/Cannabis as Treatment*]

**Consideration 3:** The Commission could collaborate with state and local stakeholders involved with youth education and safety to better educate youth about cannabis use, short-and-long term effects, as well as work collaboratively to prevent youth early initiation of cannabis use. Youth education efforts should differentiate between medical and nonmedical use. [See Sections: 1) *III.C. Age of Cannabis Initiation*, 2) *III.D. Methods of Consumption*, 3) *III.F. Cannabis Knowledge and Social Norms*, 3) *III.G.1. Driving and Riding Behaviors*, and Report, *A Baseline Review and Assessment of Cannabis Use and Youth: Literature Review and Preliminary Data in Massachusetts*]

## Future Research and Data

In the US, there continues to be major barriers to conducting research with cannabis products under the Federal 1970s Controlled Substance Act and its classification as a Schedule 1 substance, the most restrictive ranking. This strict scheduling prevents researchers and policymakers from developing evidence-based clarity on clinical effects and therapeutic potential, risks of cannabis consumption, and social impacts of regulation and industry development. Epidemiologic research assessing trends with systematic survey data collection is both possible and critical. These study findings highlight the following areas that are vital to monitor with additional studies and surveillance.

Data collection and monitoring are critical for a safe and well-regulated cannabis industry. Monitoring cannabis use trends using reliable, systematic data is essential to assess changes in trends over time and to better understand the impacts of changing cannabis policy and regulations. Continued and timely monitoring would permit policymakers to make changes to prevent adverse outcomes if concerns arise.

As stated in the Commission's 2022 goals for its Executive Director, the Commission could continue collaboration with public and private sector researchers and academics, including state researchers and epidemiologists in government cannabis regulatory entities, including public health working groups to continue to identify best practice monitoring tools and learn from states with more established markets [e.g., Council of State and Territorial Epidemiologists (CSTE), Cannabis Regulators Association (CANNRA), University of Waterloo].

**Consideration 1:** Research should consider adapting more nuanced ways to assess gender in addition to sex to better understand use trends and potential disproportionate impact or risk factors associated with gender identity. Respondents are asked about their gender identity on the ICPS, but the response options place the traditional gender binary at the center (e.g., “Man”, “Woman”, “Other” or “Unstated/Don’t know”). Respondents are given the ability to write in an identity if they choose “Other”, but future work should consider including response options for common gender identities that are not on the binary, such as response options for individuals that are nonbinary, genderfluid, or agender. Including these response options would provide cleaner, easier to use data and help researchers to answer burgeoning questions about how non-cisgender individuals use and perceive cannabis. [See Section, *III.A. Demographics*]

**Consideration 2:** Research should further assess cannabis arrest rates using self-report surveillance system surveys in conjunction with criminal justice databases, such as the National Incident-Based Reporting System and municipality law enforcement data. This data would help assess discrepancies in criminal justice encounters by demographic groups. Arrest assessments at different municipality levels across the Commonwealth could also be informative to assess localized discrepancies. Additionally, studies using qualitative data could help illuminate the continued disproportionate impact of arrests of different racial/ethnic groups. Together, these studies would provide greater understanding of persons and communities disproportionately harmed by prohibition and enforcement of cannabis (often referred to as the “War on Drugs”) to rectify past harms.



**Consideration 3:** Similar to the ICPS’s subjective indicator for socio-economic status (SES), research and surveillance system surveys should assess validity of different metrics for SES for use in surveys. Traditional SES metrics, such as income level or highest year of education, may not be flexible enough to adequately account for different demographic groups, living situations, and geographic areas across the Commonwealth. These metrics would assist to better understand how different SES groups interact with the cannabis industry(ies) and understand cannabis use risks. [See Sections: 1) *III.A. Demographics* and 2) *III.J. Illicit Market*]

**Consideration 4:** Research should further assess the intersection of cannabis use and health care, including both proactive health care usage (i.e., seeking cannabis to treat a mental or physical health symptom(s) or illness(es)) and retroactive health care (i.e., seeking out health care due to cannabis use). These assessments would assist in both understanding the clinical needs of constituents and frequency and type of adverse effects of cannabis use. [See Section, *III.I. Health Care Use/ Cannabis as Treatment* and Report, *High Tetrahydrocannabinol (THC) Cannabis and Effects on the Human Body—More Research Needed. A Legislative Report and Considerations for Research and Policy*]

**Consideration 5:** Research should further assess sourcing of cannabis and cannabis products, including assessment of the scope of illicit market and the rationales for continued sourcing of illicit market products. This information could assist policymakers and regulators adjust cannabis laws and regulations to make the licensed market more appealing to consumers and patients, if that is a policy goal. Further, it could benefit the cannabis industry by highlighting consumer and patient preferences. [See Section, *III.J. Illicit Market* and Reports: 1) *A Preliminary Assessment of the Massachusetts Cannabis Industry: Literature Review and Preliminary Data in Massachusetts* and 2) *A Baseline Review and Assessment of Cannabis Use and Public Safety Part 2: 94C Violations and Social Equity: Literature Review and Preliminary Data in Massachusetts*]

**Consideration 6:** Research should further assess methods of cannabis consumption and differential risks and benefits of the consumption methods to inform both industry and regulators. The ICPS survey data shows changing trends in preference of products and consumption methods in the legalized cannabis market(s). This information warrants continued collection and assessment to determine correlations, and even casual relationships, between types of consumption and public health impacts, as the 2019 vaporizer illness demonstrated. Understanding relationships between products, consumption preferences, and effects on cannabis users can provide information to improve medical marijuana recommendations, products, and the Commonwealth’s overall program. Further, it can point licensed Marijuana Enterprises and Marijuana Treatment Centers to efforts that enhance the consumer’s and patient’s experience, attracting them to the regulated market. Finally, this information would be useful for future consideration of adult-use and medical marijuana regulations, particularly as the Commission evaluates relatively new license types like delivery and social consumption sites. [See Sections: *III.D. Methods of Consumption* and *IV. Considerations: Education and Prevention* (Considerations 1-3), and Reports: 1) *High Tetrahydrocannabinol (THC) Cannabis and Effects on the Human Body—More Research Needed. A Legislative Report and Considerations for*

**Consideration 7:** Research should assess heterogeneity of municipality-level policies and potential effects, such as allowance for retail stores, host community agreements, permission for social consumption sites, and other provisions. Local policies impact access to regulated cannabis for consumers and patients and the development of a diverse, inclusive cannabis industry. [See Section, *III.J. Illicit Market* and Report, *Identifying Disproportionately Impacted Areas by Cannabis Prohibition in Massachusetts*]

**Consideration 8:** To comprehensively understand trends among different groups in the population at large, the Commission could collaborate and participate in other studies with systematic data collection of metrics applicable to the Commission's research agenda. The Commonwealth and its relevant agencies could work collaboratively with researchers to define priority areas of research and consistent data metrics to monitor cannabis use trends and outcomes systematically in Massachusetts. Given the varying data collection mechanisms implemented across the Commonwealth and its agencies, the state could add metrics to pre-existing surveillance systems to more accurately assess types, methods, frequency, and quantity patterns of cannabis use among different population groups (e.g., age, sex/gender, race/ethnicity, urban/suburban/rural, and socioeconomic status), and partner with health systems to assess adverse clinical health effects, such as cannabis use disorders, acute psychosis, and co-occurring mental health and cannabis use disorders.

- Seek to collaborate with researchers in healthcare systems and college health centers to monitor the rates of cannabis use disorder, and adults and emerging adults presenting to any healthcare setting with acute cannabis use symptoms or related cannabis use health concerns.
- Seek to collaborate with researchers in the primary and secondary educational systems to monitor changing norms and use patterns among youth to create best practices for prevention, intervention, and education.
- Assess metrics in ongoing data collection mechanisms in the Commonwealth, including groups not assessed in the current study. For example, the Pregnancy Risk Assessment Monitoring System (PRAMS) to assess cannabis use in prenatal and breastfeeding women, two at-risk cohorts, and perceived social norms of cannabis use during pregnancy.
- Continue collaboration with the Council of State and Territorial Epidemiologists, including assessment of optimal Internal Classification of Diseases (ICD) codes for monitoring purposes and systematically monitor and report incidences of cannabis-related ICD-9 and ICD-10 codes in health-care settings, to better understand adult and emerging adult cannabis use and cannabis-related clinical outcomes.
- Continue collaboration with University of Waterloo on the ICPS to continue to assess cannabis use and behaviors, including information about the illicit cannabis market and modes of consumption, two critical but currently under-studied metrics
- Continue collaboration with researchers at Boston Children's Hospital, where the Poison Control Center is housed, to systematically code and report Poison Control Center data related to cannabis exposures and types of products of exposure.

## V. References

1. Bridgeman, M. B., & Abazia, D. T. (2017). Medicinal Cannabis: History, Pharmacology, And Implications for the Acute Care Setting. *Pharmacy and Therapeutics*, 42(3), 180–188.
2. US Drug Enforcement Agency. (n.d.). *The Controlled Substances Act*. Retrieved May 2, 2022, from <https://www.dea.gov/drug-information/csa>
3. Lipari, R. N. (2018). *Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health*. 82.
4. Johnston, L. D., Miech, R. A., O'Malley, P. M., Bachman, J. G., Schulenberg, J. E., & Patrick, M. E. (2019). *Monitoring the Future 2019 Overview: Key Findings on Adolescent Drug Use*. 126.
5. Centers for Disease Control and Prevention. (2020). Youth Risk Behavior Surveillance—United States, 2019. *Morbidity and Mortality Weekly Report*, 69(1), 88.
6. Massachusetts Department of Public Health. (2016). *A Profile of Health Among Massachusetts Adults, 2016*. 69.
7. US Census Bureau. (2020). *Massachusetts: 2020 Census*. Census.Gov. <https://www.census.gov/library/stories/state-by-state/massachusetts-population-change-between-census-decade.html>
8. Meier, M. H., Docherty, M., Leischow, S. J., Grimm, K. J., & Pardini, D. (2019). Cannabis Concentrate Use in Adolescents. *Pediatrics*, 144(3), e20190338. <https://doi.org/10.1542/peds.2019-0338>

9. Volkow, N. D., Baler, R. D., Compton, W. M., & Weiss, S. R. B. (2014). Adverse Health Effects of Marijuana Use. *The New England Journal of Medicine*, 370(23), 2219–2227. <https://doi.org/10.1056/NEJMra1402309>
10. Volkow, N. D., Swanson, J. M., Evins, A. E., DeLisi, L. E., Meier, M. H., Gonzalez, R., Bloomfield, M. A. P., Curran, H. V., & Baler, R. (2016). Effects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review. *JAMA Psychiatry*, 73(3), 292–297. <https://doi.org/10.1001/jamapsychiatry.2015.3278>
11. Freeman, T. P., & Winstock, A. R. (2015). Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. *Psychological Medicine*, 45(15), 3181–3189. <https://doi.org/10.1017/S0033291715001178>
12. Murray, R. M., Quigley, H., Quattrone, D., Englund, A., & Di Forti, M. (2016). Traditional marijuana, high-potency cannabis and synthetic cannabinoids: Increasing risk for psychosis. *World Psychiatry: Official Journal of the World Psychiatric Association (WPA)*, 15(3), 195–204. <https://doi.org/10.1002/wps.20341>
13. Colorado Department of Public Health & Environment. (2019). *Healthy Kids Colorado Survey and Smart Source Information*. <https://cdphe.colorado.gov/hkcs>
14. Goodman, S., & Hammond, D. (2022). Perceptions of the health risks of cannabis: Estimates from national surveys in Canada and the United States, 2018–2019. *Health Education Research*, 37(2), 61–78. <https://doi.org/10.1093/her/cyac006>

## VI. Appendices

### Appendix I: Acronyms

Acronym	Meaning
<b>BRFSS</b>	Behavioral Risk Factor Surveillance System
<b>CAOA</b>	Cannabis Administration and Opportunity Act
<b>CBD</b>	Cannabidiol
<b>CNB</b>	Cannabis Control Commission
<b>CSA</b>	Controlled Substance Act
<b>CUD</b>	Cannabis Use Disorder
<b>DEA</b>	Drug Enforcement Agency
<b>FDA</b>	US Food and Drug Administration
<b>ID</b>	Identification
<b>MA</b>	Massachusetts
<b>ME</b>	Marijuana Establishment
<b>MORE</b>	Marijuana Opportunity Reinvestment and Expungement Act
<b>MTC</b>	Marijuana Treatment Facility
<b>MTF</b>	Monitoring the Future
<b>N or n</b>	Sample
<b>NA</b>	Not Applicable
<b>NCSL</b>	National Conference of State Legislatures
<b>NSDUH</b>	National Survey on Drug Use and Health
<b><i>p</i></b>	Probability value (“p-value”); testing the likelihood that results did not occur due to chance
<b>PSU</b>	Primary Sampling Unit
<b>THC</b>	Tetrahydrocannabinol
<b>US</b>	United States
<b>YRBSS</b>	Youth Risk Behavioral Surveillance System

## Appendix II: International Cannabis Policy Study (ICPS) Survey Metrics

Section	Short-Form	Whole Question	Response Options
<b>III.A. Demographics</b>	<b>Age</b>	“How old are you today?”	Number, 0-99
	<b>Student Status</b>	“Are you currently a student or will you be going to school next term?”	1= Yes 2= No -77=Don’t know -88=Refuse to answer
	<b>Sex</b>	“What sex were you assigned at birth, on your original birth certificate?”	1= Female 2= Male -77=Don’t know -88=Refuse to answer
	<b>Gender</b>	“How would you describe your gender today? (Select one).”	1= Woman 2= Man 3= Other: _____ 77= Don’t know 88= Refuse to answer
	<b>Race</b>	“What race do you consider yourself to be?”	1= White 2= American Indian or Alaskan Native 3= Asian 4= Black or African American 5= Native Hawaiian or Pacific Islander 6= Other / 2+ races/Unstated
	<b>Ethnicity</b>	“Do you consider yourself to be Hispanic, Latino, or of Spanish origin? Spanish, Hispanic or Latino people may be of any race. If you are not sure, please see the list of Hispanic or Latino categories below.”	1= Yes 2= No 77= Don’t know 88 = Refuse to answer
	<b>Income Adequacy</b>	Thinking about your family’s income, how difficult or easy is it to make ends meet?	1= Very difficult 2= Difficult 3= Neither easy nor difficult 4= Easy 5= Very easy 77= Don’t know 88= Refuse to answer
<b>III.B. Use Frequency</b>	<b>Use Frequency</b>	“How often do you use marijuana?”	0 = Never user 1 = Used more than 12 months ago 2 = Past 12-month user 3 = Monthly user

			4 = Weekly user 5 = Daily/almost daily user
<b>III.C. Age of Cannabis Initiation</b>	<b>Age of Cannabis Initiation</b>	“How old were you when you first used marijuana? Enter age in years:_____”	Number, 0-99
<b>III.D. Methods of Consumption</b>	Methods of consumption	<p>“Have you used marijuana in any of the following ways?”</p> <p><b>Note:</b> This question is asked separately as a yes/no question for each mode of use.</p>	<p>1 = No 2 = Yes:</p> <p><b>Concentrates:</b> Concentrates (e.g., wax, shatter, budder)</p> <p><b>Drinks:</b> Drinks (marijuana cola, tea, or coffee)</p> <p><b>Edibles:</b> Edibles/foods</p> <p><b>Flower:</b> Dried herb (smoked or vaped)</p> <p><b>Hash/kief:</b> Hash or kief</p> <p><b>Oils, Oral:</b> Cannabis oils or liquids taken orally (e.g., drops or capsules)</p> <p><b>Oils, Vaporized:</b> Cannabis oils or liquids for vaping</p> <p><b>Tinctures:</b> Tinctures (concentrated amounts ingested orally or taken under the tongue)</p> <p><b>Topicals:</b> Topical ointments (e.g., skin lotions or bath products)</p>
<b>III.E. Sources of Cannabis</b>	Sources of cannabis	<p>“In the past 12 months have you gotten any type of marijuana from the following sources?”</p> <p><b>Note:</b> This question is asked separately as a yes/no question for each source option.</p>	<p>0 = No 1 = Yes:</p> <p><b>Dealer:</b> From a dealer (in person)</p> <p><b>Delivery service:</b> Internet delivery service or mail order</p> <p><b>Family or friend:</b> From a family member or friend</p>

			<p><b>Self-grown:</b> I made or grew my own</p> <p><b>Licensed store:</b> From a store, co-operative or dispensary (in person)</p>
<b>IV. Knowledge and Social Norms</b>	<b>Should cannabis be legal?</b>	Should the use of recreational (non-medical) marijuana be...?	<p>0 = Illegal</p> <p>1 = Legal</p>
	<b>Questions/ Percent Correct</b>	<p>The percent of questions about cannabis answered correctly. Respondents were asked nine questions about the health effects of cannabis with scientifically supported correct answers.</p> <p><b>QUESTIONS:</b></p> <p>Q1. Can marijuana smoke be harmful?</p> <p>Q2. Can it be harmful to use marijuana when pregnant or breastfeeding?</p> <p>Q3. Can it be dangerous to drive or operate machinery after using marijuana?</p> <p>Q4. Can marijuana be addictive?</p> <p>Q5. Can regular marijuana use increase the risk of psychosis and schizophrenia?</p> <p>Q6. Are teenagers at greater risk of harm from using marijuana than adults?</p> <p>Q7. Can using marijuana cause diabetes?</p>	<p>Percent Correct = Number correct/Number attempted</p> <p><b>ANSWERS:</b></p> <p>Q1. Yes (Correct response) No, Maybe or Don't know (Incorrect response)</p> <p>Q2. Yes (Correct response) No, Maybe or Don't know (Incorrect response)</p> <p>Q3. Yes (Correct response) No, Maybe or Don't know (Incorrect response)</p> <p>Q4. Yes (Correct response) No, Maybe or Don't know (Incorrect response)</p> <p>Q5. Yes (Correct response) No, Maybe or Don't know (Incorrect response)</p> <p>Q6. Yes (Correct response) No, Maybe or Don't know (Incorrect response)</p> <p>Q7. No (Correct response) Yes, Maybe or Don't know (Incorrect response)</p> <p>Q8. No (Correct response)</p>



		Q8. Can marijuana or CBD help prevent or cure cancer?	Yes, Maybe or Don't know (Incorrect response)
		Q9. Can high-THC marijuana products negatively affect memory and concentration?	Q9. Yes (Correct response) No, Maybe or Don't know (Incorrect response)
	<b>Friends Using (Of Top 5)</b>	How many of your five closest friends use marijuana?	1= None 2= One 3= Two 4= Three 5= Four 6= Five 77= Don't know 88= Refuse to answer
<b>V.A. Driving Behaviors</b>	<b>Cannabis Driver</b>	Have you ever driven a vehicle (e.g., car, snowmobile, motor boat, or an off-road vehicle (ATV)) within 2 hours of using marijuana?	0= No, never or not in the past 12 months 1= Yes, in the past 12 months -77= Don't know
	<b>Passenger to Cannabis Driver</b>	Have you ever been a passenger in a vehicle (e.g., car, snowmobile, motor boat, or an off-road vehicle (ATV)) driven by someone who had been using marijuana in the last 2 hours?	0= No, never or not in the past 12 months 1= Yes, in the past 12 months -77= Don't know
	<b>Drive Plan</b>	Have you ever planned ahead or decided NOT to drive to avoid driving high?	1= Yes 2= No 77= Don't know 88= Refuse to answer
<b>V.B. Use at Work</b>	<b>Use at Work</b>	In the past 30 days, have you used marijuana at work (including breaks) or within 2 hours of starting work?	1= Yes 2= No 3= Not applicable – I have not worked in the past 30 days 77= Don't know 88= Refuse to answer
<b>V.C. Poly-Substance Use</b>	<b>Poly Use of Cannabis with Other Substances</b>	“Which substances have you used on the same occasion with marijuana in the past 12 months?”	1 = No 2 = Yes:  <b>Use with Alcohol:</b> Alcohol  <b>Use with Cigarettes:</b> Tobacco cigarettes

		<p><b>Note:</b> This question is asked separately as a yes/no question for each category of substance.</p>	<p><b>Use with E-Cigarettes:</b> E-cigarettes / vaped nicotine</p> <p><b>Use with Illicit Substances:</b></p> <p><b>- Amphetamines:</b> Amphetamines (e.g., speed, crystal meth or ice)</p> <p><b>-MDMA:</b> MDMA (e.g., ecstasy, Molly, E, X)</p> <p><b>-Hallucinogens:</b> Hallucinogens (e.g., LSD, acid, PCP, magic mushrooms or ‘shrooms’, mescaline, peyote)</p> <p><b>-Cocaine:</b> Cocaine (e.g., crack, blow, snow)</p> <p><b>-Heroin:</b> Heroin (e.g., smack, dope), illegal fentanyl, or other illegal/street opioids</p> <p><b>-Rx Painkillers:</b> Prescription pain relievers to get high (e.g., oxycodone, hydrocodone)</p> <p><b>-Other Rx Drugs:</b> Other prescription medication to get high (e.g., Adderall, Valium)</p>
<p><b>VI.A. Health Care Use/Cannab is as Treatment</b></p>	<p><b>Seeking of Medical Treatment</b></p>	<p>In the past 12 months, did you seek medical help for any adverse or negative health effect(s) caused by using marijuana?</p>	<p>1= Yes 2= No 77= Don’t know 88= Refuse to answer</p>
	<p><b>Use to Manage Mental Health</b></p>	<p>Have you ever used marijuana to improve or manage symptoms for any of the following: SELECT ALL THAT APPLY.</p>	<p>0 = No 1 = Yes:</p> <p><b>Anxiety:</b> Anxiety (including phobia, obsessive-compulsive disorder or a panic disorder)</p>

		<p><b>Depression:</b> Depression (including dysthymia)</p> <p><b>PTSD:</b> Post-traumatic stress disorder (PTSD) or traumatic event (e.g., abuse or loss)</p> <p><b>Bipolar:</b> Bipolar disorder, mania, or borderline personality disorder</p> <p><b>Psychosis:</b> Psychosis (e.g., paranoia, disorganized thinking, hearing voices that others can't hear) or Dissociative Identity Disorder</p> <p><b>Schizophrenia:</b> Schizophrenia</p> <p><b>Alcohol/Drug Use:</b> Alcohol or other drug use</p> <p><b>Eating Disorder:</b> Eating disorder</p> <p><b>ADD/ADHD:</b> ADD/ADHD</p> <p><b>Other:</b> Other significant emotional or mental health problem (we'll ask about pain, sleep, and physical health symptoms) on the next screen):_____</p>
	<p><b>Use to Manage Physical Health</b></p>	<p>Have you ever used marijuana to improve or manage symptoms for any of the following: SELECT ALL THAT APPLY.</p> <p>0 = No 1 = Yes:</p> <p><b>Headaches/Migraine:</b> Headaches/migraines</p> <p><b>Pain:</b> Pain (including arthritis, neuropathy or premenstrual syndrome)</p> <p><b>Nausea:</b> Nausea/vomiting or chemotherapy symptoms</p> <p><b>Lack of appetite:</b> Lack of appetite</p> <p><b>Seizures:</b> Seizures</p>

			<p><b>Muscle spasms:</b></p> <p><b>Cancer:</b> To shrink tumors or treat cancer</p> <p><b>Insomnia:</b> Problems sleeping</p> <p><b>Digestion:</b> Digestion/gastrointestinal issues (Crohn's Disease, colitis, irritable bowel syndrome, inflammatory bowel disease, etc.)</p> <p><b>Fibromyalgia:</b> Fibromyalgia</p> <p><b>Other:</b> Other condition(s) (please specify): _____</p>
<b>VII.A. Percent Legal Cannabis Purchase</b>	<b>Percent Legal Purchase: All</b>	Overall, how much of the marijuana that you used in the past 12 months was purchased from LEGAL/AUTHORIZED sources? ENTER % FROM LEGAL SOURCES: _____ %	A number, 0-100
	<b>Percent Legal Purchase: Concentra tes</b>	Overall, about what percentage (%) of the concentrate that you used in the past 12 months came from LEGAL/AUTHORIZED sources? ENTER NUMBER: _____ %	A number, 0-100
	<b>Percent Legal Purchase: Drinks</b>	What percentage (%) of the marijuana drinks that you drank in the past 12 months came from LEGAL/AUTHORIZED sources? ENTER NUMBER: _____ %	A number, 0-100
	<b>Percent Legal Purchase: Edibles</b>	What percentage (%) of the edibles that you ate in the past 12 months came from LEGAL/AUTHORIZED sources? ENTER NUMBER: _____ %	A number, 0-100

	<b>Percent Legal Purchase: Flower</b>	Overall, about what percentage (%) of the dried herb that you used in the past 12 months came from LEGAL/AUTHORIZED sources? ENTER NUMBER: _____ %	A number, 0-100
	<b>Percent Legal Purchase: Oils, Oral</b>	Overall, about what percentage (%) of the oil or liquid drops that you used in the past 12 months came from LEGAL/AUTHORIZED sources? ENTER NUMBER: _____ %	A number, 0-100
	<b>Percent Legal Purchase: Oils, Vaporized</b>	Overall, about what percentage (%) of the oil or liquid that you VAPED in the past 12 months came from LEGAL/AUTHORIZED sources? ENTER NUMBER: _____ %	A number, 0-100
	<b>Percent Legal Purchase: Tinctures</b>	Overall, about what percentage (%) of the tinctures that you used in the past 12 months came from LEGAL/AUTHORIZED sources? ENTER NUMBER: _____ %	A number, 0-100
	<b>Percent Legal Purchase: Topicals</b>	Overall, about what percentage (%) of the topicals that you used in the past 12 months came from LEGAL/AUTHORIZED sources? ENTER NUMBER: _____ %	A number, 0-100
<b>VII.B. Reasons for Avoiding Legal Purchase</b>	<b>Reasons for purchasing illicit cannabis</b>	What were the main reasons you bought from illegal/unauthorized sources instead of legal/authorized sources? SELECT ALL THAT APPLY.	<p><b>High Prices:</b> Legal sources had higher prices</p> <p><b>Less Convenient:</b> Legal sources were less convenient</p> <p><b>Too Far:</b> Legal stores were too far away/there are none where I live</p>

			<p><b>Dealer Loyalty:</b> Loyalty to my dealer</p> <p><b>Not Anonymous:</b> I wanted to stay anonymous</p> <p><b>Requires ID:</b> Legal sources require ID</p> <p><b>Product not offered legally:</b> Legal sources didn't sell the products I wanted</p> <p><b>Cannot buy legally:</b> I can't legally buy marijuana where I live</p> <p><b>Low quality in legal market:</b> Legal sources had lower-quality marijuana</p> <p><b>Low supply in legal market:</b> Legal sources had low supply or ran out</p>
<b>VII.C. History of Cannabis Arrests</b>	<b>History of Cannabis Arrests</b>	<b>Have you ever been arrested for any of the following cannabis offences...? SELECT ALL THAT APPLY.</b>	<p>0 = No 1 = Yes:</p> <p><b>Possession:</b> Cannabis possession</p> <p><b>Distribution:</b> Cannabis trafficking, cultivation or importation</p>